<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">75132</article-id><article-id pub-id-type="doi">10.7554/eLife.75132</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>P2Y1 purinergic receptor identified as a diabetes target in a small-molecule screen to reverse circadian β-cell failure</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-259448"><name><surname>Marcheva</surname><given-names>Biliana</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8697-2625</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-259449"><name><surname>Weidemann</surname><given-names>Benjamin J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3747-2744</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-259450"><name><surname>Taguchi</surname><given-names>Akihiko</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund11"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-259451"><name><surname>Perelis</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-259452"><name><surname>Ramsey</surname><given-names>Kathryn Moynihan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0691-7835</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-259453"><name><surname>Newman</surname><given-names>Marsha V</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-259454"><name><surname>Kobayashi</surname><given-names>Yumiko</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-3333"><name><surname>Omura</surname><given-names>Chiaki</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-92150"><name><surname>Manning Fox</surname><given-names>Jocelyn E</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-249893"><name><surname>Lin</surname><given-names>Haopeng</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund12"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-249897"><name><surname>Macdonald</surname><given-names>Patrick E</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund13"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-1410"><name><surname>Bass</surname><given-names>Joseph</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1602-8601</contrib-id><email>j-bass@northwestern.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/000e0be47</institution-id><institution>Department of Medicine, Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03cxys317</institution-id><institution>Division of Endocrinology, Metabolism, Hematological Science and Therapeutics, Department of Bio-Signal Analysis, Yamaguchi University, Graduate School of Medicine, 1-1-1</institution></institution-wrap><addr-line><named-content content-type="city">Yamaguchi</named-content></addr-line><country>Japan</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00t8bew53</institution-id><institution>Ionis Pharmaceuticals, Inc</institution></institution-wrap><addr-line><named-content content-type="city">Carlsbad</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0160cpw27</institution-id><institution>Department of Pharmacology, Alberta Diabetes Institute, University of Alberta</institution></institution-wrap><addr-line><named-content content-type="city">Edmonton, AB</named-content></addr-line><country>Canada</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kramer</surname><given-names>Achim</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/001w7jn25</institution-id><institution>Charite Universitaetsmedizin Berlin</institution></institution-wrap><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Stainier</surname><given-names>Didier YR</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0165r2y73</institution-id><institution>Max Planck Institute for Heart and Lung Research</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>21</day><month>02</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e75132</elocation-id><history><date date-type="received" iso-8601-date="2021-10-29"><day>29</day><month>10</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-01-21"><day>21</day><month>01</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-11-05"><day>05</day><month>11</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.11.05.467499"/></event></pub-history><permissions><copyright-statement>© 2022, Marcheva et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Marcheva et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-75132-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-75132-figures-v1.pdf"/><abstract><p>The mammalian circadian clock drives daily oscillations in physiology and behavior through an autoregulatory transcription feedback loop present in central and peripheral cells. Ablation of the core clock within the endocrine pancreas of adult animals impairs the transcription and splicing of genes involved in hormone exocytosis and causes hypoinsulinemic diabetes. Here, we developed a genetically sensitized small-molecule screen to identify druggable proteins and mechanistic pathways involved in circadian β-cell failure. Our approach was to generate β-cells expressing a nanoluciferase reporter within the proinsulin polypeptide to screen 2640 pharmacologically active compounds and identify insulinotropic molecules that bypass the secretory defect in CRISPR-Cas9-targeted clock mutant β-cells. We validated hit compounds in primary mouse islets and identified known modulators of ligand-gated ion channels and G-protein-coupled receptors, including the antihelmintic ivermectin. Single-cell electrophysiology in circadian mutant mouse and human cadaveric islets revealed ivermectin as a glucose-dependent secretagogue. Genetic, genomic, and pharmacological analyses established the P2Y1 receptor as a clock-controlled mediator of the insulinotropic activity of ivermectin. These findings identify the P2Y1 purinergic receptor as a diabetes target based upon a genetically sensitized phenotypic screen.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>Circadian rhythms – ‘inbuilt’ 24-hour cycles – control many aspects of behaviour and physiology. In mammals, they operate in nearly all tissues, including those involved in glucose metabolism. Recent studies have shown that mice with faulty genes involved in circadian rhythms, the core clock genes, can develop diabetes.</p><p>Diabetes arises when the body struggles to regulate blood sugar levels. In healthy individuals, the hormone insulin produced by beta cells in the pancreas regulates the amount of sugar in the blood. But when beta cells are faulty and do not generate sufficient insulin levels, or when insulin lacks the ability to stimulate cells to take up glucose, diabetes can develop.</p><p>Marcheva, Weidemann, Taguchi et al. wanted to find out if diabetes caused by impaired clock genes could be treated by targeting pathways regulating the secretion of insulin. To do so, they tested over 2,500 potential drugs on genetically modified beta cells with faulty core clock genes. They further screened the drugs on mice with the same defect in their beta cells.</p><p>Marcheva et al. identified one potential compound, the anti-parasite drug ivermectin, which was able to restore the secretion of insulin. When ivermectin was applied to both healthy mice and mice with faulty beta cells, the drug improved the control over glucose levels by activating a specific protein receptor that senses molecules important for storing and utilizing energy.</p><p>The findings reveal new drug targets for treating forms of diabetes associated with deregulation of the pancreatic circadian clock. The drug screening strategy used in the study may also be applied to reveal mechanisms underlying other conditions associated with disrupted circadian clocks, including sleep loss and jetlag.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>circadian clock</kwd><kwd>high-throughput screen</kwd><kwd>diabetes</kwd><kwd>ivermectin</kwd><kwd>purinergic receptor</kwd><kwd>insulin</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>R01DK090625</award-id><principal-award-recipient><name><surname>Bass</surname><given-names>Joseph</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>R01DK127800</award-id><principal-award-recipient><name><surname>Bass</surname><given-names>Joseph</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>R01DK050203</award-id><principal-award-recipient><name><surname>Bass</surname><given-names>Joseph</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>R01DK113011</award-id><principal-award-recipient><name><surname>Bass</surname><given-names>Joseph</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>P01AG011412</award-id><principal-award-recipient><name><surname>Bass</surname><given-names>Joseph</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>R01AG065988</award-id><principal-award-recipient><name><surname>Bass</surname><given-names>Joseph</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008871</institution-id><institution>Juvenile Diabetes Research Foundation United States of America</institution></institution-wrap></funding-source><award-id>17-2013-511</award-id><principal-award-recipient><name><surname>Bass</surname><given-names>Joseph</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100017011</institution-id><institution>Chicago Biomedical Consortium</institution></institution-wrap></funding-source><award-id>S-007</award-id><principal-award-recipient><name><surname>Bass</surname><given-names>Joseph</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>DK007169</award-id><principal-award-recipient><name><surname>Marcheva</surname><given-names>Biliana</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>F30DK116481</award-id><principal-award-recipient><name><surname>Weidemann</surname><given-names>Benjamin J</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007664</institution-id><institution>Manpei Suzuki Diabetes Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Taguchi</surname><given-names>Akihiko</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution>Sino-Canadian Studentship</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lin</surname><given-names>Haopeng</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><award-id>CIHR: 148451</award-id><principal-award-recipient><name><surname>Macdonald</surname><given-names>Patrick E</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A genetically sensitized drug screen identifies a circadian diabetes target and establishes a novel discovery pathway to treat β-cell failure.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Type 2 diabetes is an escalating epidemic involving gene-environment interactions that culminate in β-cell failure and insulin resistance. Recent epidemiological evidence has shown that shift work and sleep disturbance are environmental risk factors for diabetes (<xref ref-type="bibr" rid="bib62">Perelis et al., 2016</xref>), while experimental genetic studies have shown that clock gene disruption within the endocrine pancreas causes hypoinsulinemic diabetes (<xref ref-type="bibr" rid="bib51">Marcheva et al., 2010</xref>; <xref ref-type="bibr" rid="bib72">Sadacca et al., 2011</xref>). At the molecular level, the circadian clock is composed of an autoregulatory transcriptional loop in which CLOCK/BMAL1 activate the repressors PER1/2/3 and CRY1/2, which feedback to inhibit CLOCK/BMAL1 in a cycle that repeats itself every 24 hr. An additional stabilizing loop involving ROR/REV-ERB regulates BMAL1 expression (<xref ref-type="bibr" rid="bib41">Kim and Lazar, 2020</xref>). Recent chemical screens have identified new factors that modulate the core clock, including casein kinase 1 inhibitors that lengthen the circadian period through stabilizing PER proteins (<xref ref-type="bibr" rid="bib31">Hirota et al., 2010</xref>; <xref ref-type="bibr" rid="bib11">Chen et al., 2012</xref>), and a separate series of cryptochrome stabilizer compounds have been discovered that control glucose homeostasis in vivo (<xref ref-type="bibr" rid="bib32">Hirota et al., 2012</xref>). Modulators of clock transcription factors may also control whole animal metabolism (<xref ref-type="bibr" rid="bib29">He et al., 2016</xref>), though such compounds lack specificity (<xref ref-type="bibr" rid="bib16">Dierickx et al., 2019</xref>).</p><p>Here, we developed a high-throughput small-molecule screen to identify insulinotropic compounds that act downstream of the circadian clock rather than through modulation of the core clock itself. We reasoned that compounds that enhance insulin secretion in the setting of β-cell clock disruption might in turn uncover therapeutic targets for more common forms of diabetes mellitus (<xref ref-type="bibr" rid="bib51">Marcheva et al., 2010</xref>; <xref ref-type="bibr" rid="bib61">Perelis et al., 2015</xref>; <xref ref-type="bibr" rid="bib52">Marcheva et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Moffat et al., 2017</xref>). To do so, we generated β-cells harboring a circadian gene mutation by CRISPR-Cas9 and co-expressing a luminescent insulin reporter that has previously been used to identify factors that either activated or repressed glucose-stimulated insulin secretion (GSIS) in wild-type β-cell lines (<xref ref-type="bibr" rid="bib7">Burns et al., 2015</xref>). In our screen of 2640 drug or drug-like compounds in circadian mutant β-cells, we identified the macrolide ivermectin (IVM) as an insulinotropic compound that activates the P2Y1 purinergic receptor. We further identified the P2Y1 receptor as a direct transcriptional target of the molecular clock factor BMAL1 and a potent regulator of glucose-dependent calcium signaling. Our findings establish a chemical genetic strategy to identify novel endocrine cell therapeutics.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>High-throughput screen for chemical modulators of insulin secretion in circadian mutant β-cell</title><p>Based upon our finding that circadian genes regulate β-cell function, we developed a chemical genetic screen to identify pathways that enhance glucose-coupled insulin secretion in a cell-based model of circadian β-cell failure (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). We previously showed that clonal <italic>Bmal1<sup>-/-</sup></italic> Beta-TC-6 β-cell lines recapitulate the secretory defects observed in primary clock-deficient islets (<xref ref-type="bibr" rid="bib51">Marcheva et al., 2010</xref>; <xref ref-type="bibr" rid="bib61">Perelis et al., 2015</xref>; <xref ref-type="bibr" rid="bib52">Marcheva et al., 2020</xref>). We next generated stable WT and <italic>Bmal1<sup>-/-</sup></italic> β-cell lines with a luciferase readout for insulin secretion using an insulin-NanoLuciferase (NanoLuc)-expressing lentivirus (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). We validated the direct correspondence between insulin-NanoLuc bioluminescence and levels of peptide secretion under increasing physiological concentrations of glucose (2–20 mM; R<sup>2</sup> = 0.8937; <xref ref-type="fig" rid="fig1">Figure 1C</xref>). We further confirmed impaired insulin secretion by reduced bioluminescence in <italic>Bmal1<sup>-/-</sup></italic> compared to WT β-cell lines expressing insulin-NanoLuc in response to stimulatory concentrations of glucose (20 mM), potassium chloride, forskolin, and the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX) (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). We also validated the use of the DAG mimetic phorbol 12-myristate 13-acetate (PMA) as a positive control for the screen (<xref ref-type="fig" rid="fig1">Figure 1D–F</xref>; <xref ref-type="bibr" rid="bib61">Perelis et al., 2015</xref>). A feasibility test with a Z'-factor score of 0.69 indicated a significant separation between the distribution of bioluminescent signal from the positive (10 μM PMA + 20 mM glucose) and negative (20 mM glucose) controls, suggesting that the assay provides a suitable platform for a high-throughput screen (<xref ref-type="fig" rid="fig1">Figure 1F</xref>; <xref ref-type="bibr" rid="bib85">Zhang et al., 1999</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>High-throughput screen for chemical modulators of insulin secretion in circadian mutant β-cells.</title><p>(<bold>A</bold>) Flow chart of ‘phenotype’-driven cell-based genetic screening platform to identify molecules and pathways that enhance insulin secretion during circadian β-cell failure. (<bold>B</bold>) Schematic of insulin-NanoLuciferase (NanoLuc) fusion construct, with bioluminescence detected in the supernatant as a proxy for insulin secretion. (<bold>C</bold>) Correlation between insulin-NanoLuc bioluminescence and insulin values measured by ELISA in response to a range of glucose concentrations (2–20 mM; R<sup>2</sup> = 0.8937). (<bold>D</bold>) Insulin-NanoLuc bioluminescence following 1 hr exposure to 20 mM glucose, 30 mM KCl, and 20 mM glucose plus 2.5 µM forskolin, 500 µM 3-isobutyl-1-methylxanthine (IBMX), or 10 µM phorbol 12-myristate 13-acetate (PMA) in WT and <italic>Bmal1<sup>-/-</sup></italic> insulin-NanoLuc Beta-TC-6 cells (n = 3–10 experimental repeats/condition). (<bold>E</bold>) Drug screen design. Insulin-NanoLuc-expressing Beta-TC-6 <italic>Bmal1<sup>-/-</sup></italic> cells were plated in nine 384-well plates prior to exposure to 10 µM of each of the 2640 compounds from the Spectrum Collection in combination with 20 mM glucose. Negative (20 mM glucose alone) and positive (20 mM glucose plus 10 µM PMA) controls were included on each plate. (<bold>F</bold>) Drug screen feasibility test comparing negative (20 mM glucose only) and positive (20 mM glucose plus PMA) controls (n = 3 experimental repeats) (Z'-factor = 0.69). All values represent mean ± SEM. *p&lt;0.05, ***p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75132-fig1-v1.tif"/></fig></sec><sec id="s2-2"><title>Identification and validation of high-throughput screen lead compounds in murine islets at high and low glucose concentrations</title><p>We next used insulin-NanoLuc-expressing <italic>Bmal1<sup>-/-</sup></italic> β-cell lines to screen 2640 drugs and drug-like molecules from the Spectrum Collection (MicroSource Discovery Systems, Inc, New Milford, CT) to identify compounds that enhance insulin secretion (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Insulin-NanoLuc-expressing <italic>Bmal1<sup>-/-</sup></italic> Beta-TC-6 cells were plated at 40,000 cells/well in a total of nine 384-well plates, incubated for 3 days, and then treated for 1 hr with either (i) 20 mM glucose alone (negative control that elicits reduced insulin secretion in <italic>Bmal1<sup>-/-</sup></italic> cells), (ii) 20 mM glucose plus 10 μM of one of the 2640 compounds, or (iii) 20 mM glucose plus 10 μM PMA (positive control known to enhance insulin secretion in both <italic>Bmal1<sup>-/-</sup></italic> mouse islets and Beta-TC-6 cells) (<xref ref-type="bibr" rid="bib61">Perelis et al., 2015</xref>). Luciferase intensity from the supernatant was measured following exposure to NanoGlo Luciferase Assay Substrate (<xref ref-type="fig" rid="fig1">Figure 1E</xref>).</p><p>We initially identified 19 hit compounds that both significantly enhanced insulin secretion and elicited a response of greater than 3 standard deviations from the mean (Z-score &gt; 3) with more than a 1.25-fold increase, exceeding the upper 99% confidence interval of the negative control (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Of these, seven were excluded from further analysis because of reported toxic effects or lack of availability of the compound (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). The remaining 12 hit compounds mediate activity of ligand-gated cell surface receptors and ion channels that stimulate second messenger signaling cascades (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>; <xref ref-type="bibr" rid="bib23">Gaulton et al., 2010</xref>; <xref ref-type="bibr" rid="bib8">Carrano et al., 2017</xref>). Of these, four target ion channels (tacrine hydrochloride, suloctidil, dyclonine hydrochloride, and IVM) (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>; <xref ref-type="bibr" rid="bib37">Karlsson and Ahrén, 1992</xref>; <xref ref-type="bibr" rid="bib10">Chatelain et al., 1984</xref>; <xref ref-type="bibr" rid="bib40">Khanna et al., 2011</xref>; <xref ref-type="bibr" rid="bib12">Chen and Kubo, 2018</xref>; <xref ref-type="bibr" rid="bib19">Freeman et al., 1988</xref>; <xref ref-type="bibr" rid="bib15">de Gaetano et al., 1976</xref>; <xref ref-type="bibr" rid="bib42">Kornhuber et al., 2008</xref>; <xref ref-type="bibr" rid="bib73">Sahdeo et al., 2014</xref>; <xref ref-type="bibr" rid="bib69">Roghani et al., 1999</xref>; <xref ref-type="bibr" rid="bib34">Ikeda, 2003</xref>). Five target seven-transmembrane G-protein coupled receptors (GPCRs) that signal through phospholipase C (PLC) and diacylglycerol (DAG) to activate insulin secretion and β-cell gene transcription (benzalkonium chloride, carbachol, isoetharine mesylate, pipamperone, and IVM) (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>; <xref ref-type="bibr" rid="bib12">Chen and Kubo, 2018</xref>; <xref ref-type="bibr" rid="bib30">Higashijima et al., 1990</xref>; <xref ref-type="bibr" rid="bib68">Rinne et al., 2015</xref>; <xref ref-type="bibr" rid="bib5">Bierman, 1983</xref>; <xref ref-type="bibr" rid="bib80">Van Craenenbroeck et al., 2006</xref>; <xref ref-type="bibr" rid="bib57">Nagata et al., 2019</xref>; <xref ref-type="bibr" rid="bib67">Ratajewski et al., 2015</xref>; <xref ref-type="bibr" rid="bib59">Ohtani et al., 2011</xref>). Similar to the hit compounds of our screen, our previous results showed that carbachol, a muscarinic G<sub>q</sub>-coupled receptor agonist, and the DAG mimetic PMA rescue insulin secretion in <italic>Bmal1<sup>-/-</sup></italic> islets (<xref ref-type="bibr" rid="bib61">Perelis et al., 2015</xref>). Four additional hit compounds act as acetylcholinesterase inhibitors, promoting enhanced glucose-dependent insulin secretion in response to acetylcholine through the muscarinic GPCRs, as well as the ionotropic nicotinic acetylcholine receptors (tyrothricin, tomatine, carbachol, and tacrine hydrochloride) (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>; <xref ref-type="bibr" rid="bib9">Changeux et al., 1969</xref>; <xref ref-type="bibr" rid="bib54">Milner et al., 2011</xref>; <xref ref-type="bibr" rid="bib71">Rosenberry et al., 2008</xref>; <xref ref-type="bibr" rid="bib53">Marco and Carreiras, 2003</xref>; <xref ref-type="bibr" rid="bib44">Lang and Staiger, 2016</xref>; <xref ref-type="bibr" rid="bib76">Shih et al., 2009</xref>). One compound has been shown to promote insulin secretion by inhibition of the mitochondrial protein tyrosine phosphatase PTPM1 (alexidine hydrochloride) (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>; <xref ref-type="bibr" rid="bib17">Doughty-Shenton et al., 2010</xref>; <xref ref-type="bibr" rid="bib58">Nath et al., 2015</xref>), and another likely affects β-cell function by signaling through the mineralocorticoid receptor (deoxycorticosterone) (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>; <xref ref-type="bibr" rid="bib50">Lu et al., 2006</xref>). Finally, in addition to ion channels and GPCRs, the macrolide IVM has also been shown to signal in micromolar concentrations though several ionotropic receptors, including purinergic, GABAergic, and glycine receptors, as well as through the farnesoid X nuclear receptor (<xref ref-type="bibr" rid="bib12">Chen and Kubo, 2018</xref>; <xref ref-type="bibr" rid="bib14">Dawson et al., 2000</xref>; <xref ref-type="bibr" rid="bib77">Soltani et al., 2011</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Identification and validation of high-throughput screen lead compounds in murine islets at high and low glucose concentrations.</title><p>(<bold>A</bold>) Significant Z-scores (&gt;3 standard deviations) and fold changes (&gt;1.25-fold increase) for all 2640 screened compounds, with hit compounds indicated in blue. (<bold>B</bold>) Top 12 hit compounds identified from screen with a fold increase &gt; 1.25 and a Z-score &gt; 3, which were selected for further analysis. Known functions and published molecular pathways targeted by these compounds are indicated. (<bold>C</bold>) Model of potential mechanisms of action of the top 12 hit compounds to affect insulin secretion in the β-cell. (<bold>D</bold>) Glucose-responsive insulin secretion by ELISA at 2 mM and 20 mM glucose in WT mouse islets following exposure to four lead candidate compounds (n = 3–11 mice/compound). (<bold>E</bold>) Ivermectin (IVM) dose-response curve (n = 6–8 experimental repeats/dose), ranging from 0.078 µM to 80 µM IVM, in insulin-NanoLuciferase-expressing Beta-TC-6 cells. Shaded area represents 95% confidence intervals for the LOESS curve. All values represent mean ± SEM. **p&lt;0.01, ***p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75132-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>High-throughput screen for modulators of insulin secretion in circadian mutant β-cells and validation of lead compounds.</title><p>(<bold>A</bold>) Compound exclusion flow chart delineating exclusion criteria and numbers of compounds excluded at each validation step. (<bold>B</bold>) Hit compound validation at concentrations of 10 and 100 µM in <italic>Bmal1<sup>-/-</sup></italic> insulin-NanoLuciferase cells (n = 3/compound). All values represent mean ± SEM. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75132-fig2-figsupp1-v1.tif"/></fig></fig-group><p>10 of these 12 hit compounds were not considered for further analysis because of either the high dose required to achieve insulin secretion (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>) or because they augmented insulin release in low basal glucose (2 mM) in intact WT mouse primary islets (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). One of the remaining compounds induces hepatotoxicity after prolonged use (tacrine hydrochloride) (<xref ref-type="bibr" rid="bib21">Galisteo et al., 2000</xref>). We therefore focused our attention on IVM due to its dose-dependent enhancement of GSIS in insulin-NanoLuc-expressing Beta-TC-6 cells, as well as its robust rescue of insulin secretion in <italic>Bmal1<sup>-/-</sup></italic> islets (<xref ref-type="fig" rid="fig2">Figure 2D and E</xref>).</p></sec><sec id="s2-3"><title>Lead compound ivermectin regulates glucose-stimulated calcium flux and insulin exocytosis in <italic>Bmal1</italic> mutant islets</title><p>To test whether IVM drives GSIS in β-cell lines and primary mouse islets, we first assessed the impact of both acute treatment (1 hr) and overnight exposure (24 hr) with 10 μM IVM on the ability of WT β-cells and mouse islets to secrete insulin (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). Consistent with our initial bioluminescence assay, we observed that IVM enhanced insulin secretion in a glucose-dependent manner following both 1 hr IVM exposure and 24 hr pretreatment with IVM in β-cell lines and WT mouse islets, suggesting that both acute and longer-term exposure to IVM enhance β-cell function (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). Since there was not a significant increase in insulin secretion with overnight (approximately twofold) compared to acute (~1.5–1.6-fold) IVM exposure, further analysis of IVM as a potentiator of insulin secretion was performed only with acute treatment.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Effect of lead compound ivermectin (IVM) on glucose-stimulated insulin exocytosis and calcium flux from WT and circadian mutant β-cells.</title><p>(<bold>A</bold>) Insulin secretion (expressed as % content) assessed by ELISA at 2 mM and 20 mM glucose in WT mouse islets in response to 1 hr 10 µM IVM treatment or 24 hr 10 µM IVM pretreatment (n = 5 mice). Data was analyzed by two-way ANOVA and false discovery rate (FDR) correction for multiple testing. (<bold>B</bold>) Insulin secretion as assessed by ELISA from islets isolated from 8-month-old pancreas-specific <italic>Bmal1</italic> knockout and <italic>Bmal1<sup>flx/flx</sup></italic> mice in the presence or absence of 10 µM IVM (n = 10–11 mice/genotype). (<bold>C</bold>) Perifusion analysis of insulin secretion in islets from pancreas-specific <italic>Bmal1</italic> knockout (<italic>PdxCre;Bmal1<sup>flx/flx</sup></italic>) and <italic>Bmal1<sup>flx/flx</sup></italic> mice in response to 10 µM IVM in the presence of 20 mM glucose (n = 3 mice/genotype). (<bold>D</bold>) Insulin secretion as assessed by ELISA from islets isolated from 9- to 12-month-old male <italic>Cry1<sup>-/-</sup>;Cry2<sup>-/-</sup></italic> knockout and <italic>Cry1<sup>+/-</sup>;Cry2<sup>+/-</sup></italic> heterozygous control mice in the presence or absence of ± µM IVM (n = 4 mice/genotype). (<bold>E</bold>) Capacitance measurements in β-cells from <italic>PdxCre;Bmal1<sup>flx/flx</sup></italic> and <italic>Bmal1<sup>flx/flx</sup></italic> mouse islets treated with 10 µM IVM (n = 4–5 mice/genotype, 5–16 cells per mouse). Asterisks denote significance between <italic>PdxCre;Bmal1<sup>flx/flx</sup></italic> and <italic>PdxCre;Bmal1<sup>flx/flx</sup></italic> + IVM; plus symbols denote significance between <italic>Bmal1<sup>flx/flx</sup></italic> and <italic>PdxCre;Bmal1<sup>flx/flx</sup></italic> for all depolarization numbers indicated. */+ p&lt;0.05. (<bold>F</bold>) Capacitance measurements in β-cells from human islets treated with 10 µM IVM (n = 3 donors, 7–11 cells per donor). Capacitance and calcium data were analyzed by two-way repeated-measures ANOVA with Bonferroni correction for multiple testing. All values represent mean ± SEM. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75132-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Ivermectin (IVM) improves insulin exocytosis in diabetic mice.</title><p>(<bold>A</bold>) Insulin-NanoLuciferase (insulin-Nano-Luc) bioluminescence at 0 mM and 20 mM glucose in WT Beta-TC-6 cells in response to 1 hr 10 µM IVM treatment or 24 hr 10 µM IVM pretreatment (n = 5 experiments, 3–24 experimental repeats/experiment). Data was analyzed by two-way ANOVA and false discovery rate (FDR) correction for multiple testing. (<bold>B</bold>) Ratiometric determination of intracellular Ca<sup>2+</sup> using Fura2-AM dye in WT Beta-TC-6 cells stimulated in the presence or absence of 10 µM IVM (n = 3 experimental repeats/condition). (<bold>C</bold>) Insulin secretion in pseudoislets from WT insulin-NanoLuc-expressing Beta-TC-6 cells in response to 10 µM IVM and 5 µM isradipine (isr) (n = 3–8 experiments, 3–16 experimental repeats/experiment). p-Values were determined by Tukey’s multiple comparison tests following one-way ANOVA. (<bold>D</bold>) Ratiometric determination of intracellular Ca<sup>2+</sup> using Fura2-AM dye in WT Beta-TC-6 cells stimulated with IVM or isr (n = 3–8 experiments, 4–16 experimental repeats/experiment). (<bold>E</bold>) Perifusion analysis of insulin secretion from WT insulin-NanoLuc pseudoislets in response to 10 µM IVM in the presence of 20 mM glucose (n = 6 experimental repeats/condition). (<bold>F</bold>) Glucose levels at the indicated time points following an intraperitoneal injection of glucose (2 g/kg body weight) at ZT2 after 14 days of daily intraperitoneal injections with 1.3 mg/kg body weight of IVM (n = 8 mice/genotype). Glucose levels were analyzed by two-way repeated-measures ANOVA with Bonferroni multiple testing. (<bold>G</bold>) Insulin secretion as assessed by ELISA from islets isolated from 4-month-old <italic>Akita</italic> mice in the presence or absence of 10 μM IVM (n = 5–6 mice/genotype). All values represent mean ± SEM. **p&lt;0.01, ***p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75132-fig3-figsupp1-v1.tif"/></fig></fig-group><p>Chemical energy from ATP generated by glucose metabolism within the β-cell triggers closure of the sulfonylurea-linked potassium channel, depolarization of the plasma membrane, and opening of voltage-gated calcium channels, leading to stimulus-secretion coupling. To assess the mechanism of IVM-induced insulin secretion, we next monitored real-time calcium influx using ratiometric fluorescence imaging in WT β-cells in the presence of both glucose and IVM. We observed an immediate and robust glucose-stimulated intracellular calcium response within 2 min of IVM stimulation (p&lt;0.05) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Importantly, this effect was only observed in the presence of high glucose, consistent with results of our initial NanoLuc 384-well plate screening and subsequent ELISA-based analyses of GSIS. In contrast, the Ca<sup>2+</sup> channel inhibitor isradipine completely suppressed Ca<sup>2+</sup> influx and insulin secretion (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C and D</xref>; <xref ref-type="bibr" rid="bib4">Berjukow et al., 2000</xref>). To determine whether increased calcium influx corresponded with productive insulin release following IVM treatment, we used a dynamic perifusion system to directly measure NanoLuc activity in eluates harvested from IVM-treated β-cells every 2 min over the course of 30 min following stimulation with either 20 mM glucose or 20 mM glucose plus 10 µM IVM (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). IVM significantly increased insulin release during the initial burst of secretion within the first 12 min post-stimulation (p&lt;0.05) and continued to enhance insulin secretion during the remainder of the stimulation period (12–30 min), consistent with continuous release of reserve insulin granules (<xref ref-type="bibr" rid="bib70">Rorsman and Renström, 2003</xref>).</p><p>Since our cell-based studies indicated that IVM stimulates GSIS within immortalized β-cell lines, we next sought to determine whether IVM restores insulin secretion in the context of circadian disruption within primary islets, which are composed of multiple hormone-releasing cell types (<xref ref-type="bibr" rid="bib2">Arrojo E Drigo et al., 2020</xref>). To test this idea, we administered IVM to mouse islets isolated from pancreas-specific <italic>Bmal1<sup>-/-</sup></italic> mice, revealing a 3.3-fold elevation of GSIS following exposure to the drug in the <italic>Bmal1</italic> mutant islets (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Furthermore, perifusion experiments in islets from <italic>Bmal1</italic> mutant mice revealed that IVM significantly increased insulin release during both the initial burst of secretion (first 12 min post-stimulation) and during the sustained release (12–30 min) in both WT and <italic>Bmal1</italic> mutant islets (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Additionally, we observed a similar 2.9-fold increase in GSIS following administration of IVM to islets isolated from an independent mouse model of circadian disruption (<italic>Cry1<sup>-/-</sup>;Cry2<sup>-/-</sup></italic> mice) (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), suggesting that IVM ameliorates secretory defects caused by disruption of the circadian clock network. To determine if IVM can improve glucose homeostasis in diabetic animals, we next tested the effects of chronic IVM administration in the well-characterized C57BL/6-<italic>Ins2<sup>Akita</sup></italic>/J <italic>Akita</italic> model of β-cell failure (<xref ref-type="bibr" rid="bib84">Yoshioka et al., 1997</xref>). Daily intraperitoneal IVM (1.3 mg/kg body weight) was administered to <italic>Akita</italic> mice over a 14-day period (<xref ref-type="bibr" rid="bib36">Jin et al., 2013</xref>), terminating in assessment of glucose tolerance and ex vivo GSIS. Treatment with IVM significantly improved glucose tolerance and augmented glucose-stimulated insulin release from islets isolated from these mice (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F and G</xref>). Given that our prior genomic and cell physiological studies have localized the β-cell defect in circadian mutant mice to impaired insulin exocytosis (<xref ref-type="bibr" rid="bib52">Marcheva et al., 2020</xref>), and as IVM augmented insulin secretion in <italic>Bmal1</italic> mutant islets, we next sought to determine whether IVM might enhance depolarization-induced exocytosis using electrophysiological analyses (<xref ref-type="bibr" rid="bib20">Fu et al., 2019</xref>). We assessed cumulative capacitance, a measure of increased cell surface area as insulin granules fuse to the plasma membrane, in β-cells from islets of control and pancreas-specific <italic>Bmal1</italic> mutant mice, as well as from human cadaveric islets. While <italic>Bmal1</italic> mutant cells displayed reduced rates of exocytosis following direct depolarization (as indicated by reduced capacitance), 10 µM IVM treatment rescued the defect in <italic>Bmal1</italic> mutant cells, increasing cumulative capacitance from 11.0 to 20.7 fF/pF after 10 consecutive depolarization steps (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). IVM treatment also enhanced cumulative capacitance in human β-cells from 17.9 to 39.7 fF/pF (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). Together, these data show that IVM augments β-cell early calcium influx in a glucose-dependent manner to promote increased vesicle fusion and release.</p></sec><sec id="s2-4"><title>Purinergic receptor P2Y1 mediates IVM-induced insulin exocytosis</title><p>Several of the predicted targets of the insulinotropic compounds from our screen, including IVM, involve second-messenger signaling, raising the possibility that circadian disruption may be overcome by augmenting hormonal or metabolic factors that promote peptide exocytosis. IVM is a readily absorbable and potent derivative of avermectin B<sub>1</sub> that allosterically regulates several different types of cell surface receptors, including purinergic and GABA receptors, as well as nuclear transcription factors such as the farnesoid X receptor (FXR) (<xref ref-type="bibr" rid="bib36">Jin et al., 2013</xref>; <xref ref-type="bibr" rid="bib38">Khakh et al., 1999</xref>; <xref ref-type="bibr" rid="bib26">González Canga et al., 2008</xref>; <xref ref-type="bibr" rid="bib18">Estrada-Mondragon and Lynch, 2015</xref>). Since IVM augments insulin secretion in <italic>Bmal1<sup>-/-</sup></italic> cells, we hypothesized that the expression of putative IVM targets may be reduced during circadian disruption. We first identified the purinergic receptor P2Y1 (<italic>P2ry1</italic>) as the most highly expressed putative IVM target in wild-type β-cells (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). We then observed that <italic>P2ry1</italic> was one of the most highly downregulated targets in <italic>Bmal1<sup>-/-</sup></italic> cells, with mRNA expression levels reduced by ~3.1-fold (adjusted p=10<sup>–55</sup>; <xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>; GSE146916). We found decreased levels and loss in rhythmicity of <italic>P2ry1</italic> in synchronized <italic>Bmal1<sup>-/-</sup></italic> pseudoislets (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). BMAL1 chromatin immunoprecipitation-sequencing in Beta-TC-6 cells further revealed enrichment of BMAL1 chromatin binding within enhancer regions 266–41 kb upstream of the <italic>P2ry1</italic> gene transcription start site (GSE69889; <xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Finally, analysis of RNA-sequencing data from human islets (SRA accession ERP017126) indicates that <italic>P2RY1</italic> expression is enriched within β-cells among hormone-secreting cell types, with little to no detectable expression in the glucagon-secreting α cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>; <xref ref-type="bibr" rid="bib75">Segerstolpe et al., 2016</xref>). Together, these data reveal direct rhythmic control of the <italic>P2ry1</italic> gene by the β-cell circadian clock.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Purinergic receptor P2Y1 is required for ivermectin (IVM) to augment insulin exocytosis.</title><p>(<bold>A</bold>) Venn diagram of BMAL1 binding sites identified by ChIP-sequencing overlapping with differentially expressed genes identified by RNA-sequencing in <italic>Bmal1<sup>-/-</sup></italic>β-cell line compared to control cell line (top). Browser tracks and bar graph showing decreased expression of <italic>P2ry1</italic> gene in <italic>Bmal1<sup>-/-</sup></italic> cells compared to controls. BMAL1 binding sites upstream of the <italic>P2ry1</italic> gene are also indicated (bottom). (<bold>B</bold>) Bioluminescence from WT insulin-NanoLuciferase pseudoislets in response to 10 µM IVM and/or 10 µM of the P2Y1 antagonist MRS2179 (n = 3–8 experiments, 3–15 experimental repeats/experiment). (<bold>C</bold>) Ratiometric determination of intracellular Ca<sup>2+</sup> using Fura2-AM dye in WT Beta-TC-6 cells stimulated in the presence or absence of 10 µM IVM (n = 3–7 experiments, 4–19 experimental repeats/experiment). (<bold>D</bold>) Insulin secretion by ELISA in pseudoislets from <italic>P2ry1</italic> KOs and control WT and <italic>Bmal1<sup>-/-</sup></italic> Beta-TC-6 cells (n = 4 experiments, two experimental repeats/experiment). p-Values were determined by Tukey’s multiple comparison tests following two-way ANOVA. (<bold>E</bold>) First two principal components (PC1 and PC2) following unbiased principal component analysis (PCA) of DESeq2 normalized counts in WT, WT + IVM, <italic>P2yr1</italic> KO, and <italic>P2yr1</italic> KO cells (n = 4 per group). (<bold>F</bold>) Mean log<sub>2</sub>-transformed DESeq2-normalized counts in WT, WT + IVM, <italic>P2yr1</italic> KO, and <italic>P2yr1</italic> KO cells (n = 4 per group) at differentially expressed (1.5-fold, adjusted p-value&lt;0.05) transcripts identified between WT and WT + IVM treated cells. All values represent mean ± SEM. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75132-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Evidence for circadian control of <italic>P2ry1</italic>.</title><p>(<bold>A</bold>) mRNA abundance (transcripts per million [TPM]) in WT β-cells (left), DESeq2-adjusted p-values from differential expression analysis in <italic>Bmal1<sup>-/-</sup></italic> versus WT β-cells (middle left), fold change in expression in <italic>Bmal1<sup>-/-</sup></italic> versus WT β-cells (middle right), and presence or absence of an annotated BMAL1 binding site near genes of putative ivermectin (IVM) targets (right). (<bold>B</bold>) Rhythmic expression of <italic>P2ry1</italic> gene in synchronized pseudoislets from WT Beta-TC-6 cells as assessed by quantitative real-time PCR (n = 3) (false discovery rate (FDR)-adjusted p-value&lt;0.05). (<bold>C</bold>) Uniform manifold approximation and projection (UMAP) clustering analysis of single-cell expression values in single human islet cells isolated from type 2 diabetic and healthy subjects highlights distinct transcriptional profiles of β, α, δ, and γ cells marked by high levels of insulin (<italic>INS</italic>), glucagon (<italic>GCG</italic>), somatostatin (<italic>SST</italic>), or pancreatic polypeptide (<italic>PPY</italic>) mRNA, respectively. <italic>P2RY1</italic> expression is enriched in β and δ cells, and grossly excluded from α and γ cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75132-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Genetic ablation of purinergic receptor P2Y1 in Beta-TC-6 cells blunts effect of ivermectin (IVM) on gene expression.</title><p>(<bold>A</bold>) Quantitative real-time PCR screening for disruption of <italic>P2ry1</italic> gene expression (n = 3–4/genotype) (top). Decreased P2Y1 receptor protein expression by Western blot in WT and <italic>Bmal1<sup>-/-</sup></italic> Beta-TC-6 cells after genetic disruption (bottom). (<bold>B</bold>) Loss of effect of IVM on gene expression in <italic>P2ry1</italic> mutant β-cells identified by RNA-sequencing (n = 4/genotype/condition). Dots represent values that exceed 1.5-fold of the interquartile range. All values represent mean ± SEM. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. See <xref ref-type="supplementary-material" rid="fig4s2sdata1">Figure 4—figure supplement 2—source data 1</xref> and <xref ref-type="supplementary-material" rid="fig4s2sdata2">Figure 4—figure supplement 2—source data 2</xref>.</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>P2Y1 expression by Western blot.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-75132-fig4-figsupp2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s2sdata2"><label>Figure 4—figure supplement 2—source data 2.</label><caption><title>ACTIN expression by Western blot.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-75132-fig4-figsupp2-data2-v1.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75132-fig4-figsupp2-v1.tif"/></fig></fig-group><p>Based upon evidence that IVM targets purinergic receptors (<xref ref-type="bibr" rid="bib82">Weng et al., 2008</xref>; <xref ref-type="bibr" rid="bib66">Priel and Silberberg, 2004</xref>; <xref ref-type="bibr" rid="bib6">Bowler et al., 2003</xref>; <xref ref-type="bibr" rid="bib27">Hansen et al., 2008</xref>), that the predominant purinergic receptor on β-cells is P2Y1, and that BMAL1 specifically controls <italic>P2ry1</italic> amongst the purinergic receptor family in the β-cell (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A and B</xref>), we sought to test the functional role of the P2Y1 receptor in the insulinotropic action of IVM. Pharmacological inhibition of P2Y1 using a subtype-specific inhibitor, the nucleotide analog MRS2179, in the presence of both high glucose and 10 μM IVM resulted in a 52% reduction in insulin secretion by bioluminescence and a reduction in calcium influx to levels similar to those observed during high glucose alone, as assessed by Fura2-AM ratiometric determination of intracellular calcium (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>). In addition to evidence that pharmacological blockade of P2Y1 receptor signaling attenuates IVM activity, we also tested the requirement of P2Y1 receptor signaling following CRISPR-Cas9-mediated knockout of the P2Y1 receptor in both WT and <italic>Bmal1<sup>-/-</sup></italic>β-cells (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>). While IVM enhanced GSIS in WT and <italic>Bmal1<sup>-/-</sup></italic>β-cells 1.6- and 1.8-fold, respectively, IVM did not significantly enhance GSIS in cells lacking the P2Y1 receptor (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Similar to the pharmacological findings with the P2Y1 antagonist MRS2179, these results demonstrate a requirement for P2Y1 in IVM-induced GSIS.</p><p>P2Y1 receptor signaling involves activation of Ca<sup>2+</sup> entry and intracellular release, which results in both acute stimulation of insulin granule trafficking and activation of transcription factors that may be involved in β-cell function (<xref ref-type="bibr" rid="bib45">Léon et al., 2005</xref>; <xref ref-type="bibr" rid="bib39">Khan et al., 2014</xref>; <xref ref-type="bibr" rid="bib3">Balasubramanian et al., 2010</xref>). To analyze gene expression changes induced by P2Y1 activation, we performed RNA-sequencing to compare the IVM response within both WT and <italic>P2ry1<sup>-/-</sup></italic> β-cells following stimulation with glucose or glucose plus IVM. Principal component analysis (PCA) was performed using log-transformed count data from the top 500 most variable genes across all samples (<xref ref-type="bibr" rid="bib49">Love et al., 2014</xref>). This revealed distinct patterns in mRNA expression between IVM- and control-treated WT cells along PC2, while there was no separation between IVM- and control-treated <italic>P2ry1<sup>-/-</sup></italic> β-cells, suggesting that P2Y1 is required for IVM-mediated transcriptional changes in β-cells (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). In WT cells, IVM induced differential expression of 65 transcripts (1.5-fold change, adjusted p-value&lt;0.05), including upregulation of the immediate early gene <italic>Fos</italic> (<xref ref-type="bibr" rid="bib56">Murphy et al., 1991</xref>) and downregulation of <italic>Aldolase B</italic>, whose expression has been linked to reduced insulin secretion in human islets (<xref ref-type="bibr" rid="bib24">Gerst et al., 2018</xref>; <xref ref-type="fig" rid="fig4">Figure 4F</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Strikingly, none of these transcripts were significantly altered by IVM in the <italic>P2ry1<sup>-/-</sup></italic> β-cells (all adjusted p-value&gt;0.05) (<xref ref-type="fig" rid="fig4">Figure 4F</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Taken together, these data suggest that the circadian clock program controls P2Y1 expression to modulate GSIS and highlight the utility of a genetic-sensitized drug screen for identification of therapeutic targets in circadian dysregulation and diabetes.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We have identified an unexpected role for the P2Y1 receptor as a BMAL1-controlled insulinotropic factor required for enhanced β-cell glucose-stimulated Ca<sup>2+</sup> influx and insulin secretion in response to IVM. While P2Y receptors have been previously implicated in calcium and insulin secretory dynamics in β-cells, modulation has been primarily demonstrated using agonists that mimic ATP/ADP derivatives that have deleterious effects on thrombosis (<xref ref-type="bibr" rid="bib45">Léon et al., 2005</xref>; <xref ref-type="bibr" rid="bib39">Khan et al., 2014</xref>; <xref ref-type="bibr" rid="bib3">Balasubramanian et al., 2010</xref>; <xref ref-type="bibr" rid="bib22">Gąsecka et al., 2020</xref>). Little is known about P2Y1 targeting in disease states, such as circadian disruption and/or type 2 diabetes, or whether P2Y1 is controlled at a transcriptional level. Our evidence that P2Y1 is expressed under control of the circadian clock derives from analyses at the level of both chromatin binding by the core clock factor BMAL1 and genome-wide differential RNA expression analysis in circadian mutants. Intriguingly, P2X and P2Y receptors are required for Ca<sup>2+</sup> signaling in the suprachiasmatic nucleus (<xref ref-type="bibr" rid="bib48">Lommen et al., 2017</xref>; <xref ref-type="bibr" rid="bib79">Svobodova et al., 2018</xref>), yet their role in circadian regulation of peripheral tissues has not been well studied. Our data suggests that IVM action requires the presence of P2Y1 receptors in β-cells since functional ablation of the P2Y1 receptor attenuates the effect of IVM on insulin secretion in both wild-type and circadian mutant β-cells (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Our analyses reveal that pharmacological enhancement of P2Y1 receptor activity may therefore bypass pathological and circadian alterations in expression of the P2Y1 receptor in β-cells to restore insulin secretion. Recently, the P2Y1 receptor was implicated in nutrient- and ATP/ADP-dependent regulation of insulin release through an adipocyte-islet axis, further suggesting that P2RY1 may play a role in physiological regulation of islet hormone release (<xref ref-type="bibr" rid="bib65">Prentice et al., 2021</xref>). Future studies will be required to determine whether IVM affects paracrine ATP/ADP release to affect P2RY1 or whether IVM directly binds purinergic receptors in the β-cell. One possibility is that IVM may augment P2X-P2Y1 crosstalk to drive insulin secretion, which has been shown to drive Ca<sup>2+</sup> and P2Y1-dependent activation of other cell types (<xref ref-type="bibr" rid="bib82">Weng et al., 2008</xref>; <xref ref-type="bibr" rid="bib83">Woehrle et al., 2019</xref>).</p><p>Previous physiological and transcriptomic studies have shown that circadian regulation of insulin exocytosis involves control of the expression and activity of cell-surface receptors and second messenger systems (<xref ref-type="bibr" rid="bib61">Perelis et al., 2015</xref>; <xref ref-type="bibr" rid="bib25">Gil-Lozano et al., 2014</xref>). We based our drug screen on the idea that modulators of insulin secretion in cells that lack a functional clock would complement prior genomic analyses revealing circadian control of peptidergic hormone exocytosis and also to provide proof of principle that the clock can be leveraged to sensitize screening for new chemical modulators of β-cell function. This approach identified Ca<sup>2+</sup>-dependent pathways as a potential route to ameliorate circadian disruption and enhance GSIS. Previous small-molecule screens have identified glucose-dependent insulinotropic compounds in wild-type cells (<xref ref-type="bibr" rid="bib7">Burns et al., 2015</xref>). However, several of these compounds, including the anti-inflammatory bufexamac and anti-giardiasis drug lobendazole, were found to be ineffective or even inhibitory in our circadian mutant screen (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). In the future, high-throughput screens may lead to more personalized therapeutics through comparison of insulinotropic compounds identified using cells without known mutations versus those discovered in cells harboring monogenic or polygenic diabetes variants. Several of the compounds identified in our screen have been used in disease treatment and have known mechanisms of action, including the cholinergic activators carbachol and tacrine (<xref ref-type="bibr" rid="bib47">Linn et al., 1989</xref>; <xref ref-type="bibr" rid="bib13">Crismon, 1994</xref>). The identification of these compounds in our screen raises the intriguing possibility of using drug derivatives related to these molecules for type 2 diabetes treatment, particularly in the context of circadian/sleep disruption.</p><p>The study of transcriptional rhythms across the 24 hr circadian cycle has previously revealed a diverse landscape of clock-controlled genes and pathways (<xref ref-type="bibr" rid="bib86">Zhang et al., 2014</xref>). Despite the identification of thousands of tissue-specific and clock-controlled transcripts, limited advances have been made in utilizing this information to treat diseases associated with circadian disruption, including type 2 diabetes. One approach to this challenge has been to intervene and restore the molecular clock program using pharmacology (Nobiletin) (<xref ref-type="bibr" rid="bib29">He et al., 2016</xref>), micronutrient supplementation (NAD<sup>+</sup> precursors) (<xref ref-type="bibr" rid="bib46">Levine et al., 2020</xref>; <xref ref-type="bibr" rid="bib74">Sato et al., 2017</xref>), or enforced behavioral rhythms (such as time-restricted feeding) (<xref ref-type="bibr" rid="bib78">Sutton et al., 2018</xref>). However, it remains unclear how altering the whole-body clock will affect nutritional and hormonal dynamics at a cellular level. Another approach has been to directly target clock-controlled genes with known function in health and disease (<xref ref-type="bibr" rid="bib43">Lamia et al., 2008</xref>) or to look at gain/loss of circadian control in health versus disease (<xref ref-type="bibr" rid="bib63">Petrenko et al., 2020a</xref>). This approach requires an understanding of gene function within a given tissue, and thus limits the identification of novel therapeutic targets. In the studies performed here, we sought to address the challenge of connecting clock control of transcription with druggable targets by using an unbiased small-molecule drug screen, in tandem with functional genomics, to elucidate mechanisms of insulin secretory dynamics. Since the circadian timing system has been shown to not only regulate the function of mature β-cells, but also the regenerative capacity of islets in both the context of the mouse (<xref ref-type="bibr" rid="bib64">Petrenko et al., 2020b</xref>) and in human embryonic stem cell differentiation (<xref ref-type="bibr" rid="bib1">Alvarez-Dominguez et al., 2020</xref>), molecules identified in cell-based genetic screens may provide broad applicability as therapeutics.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Bmal1</italic></td><td align="left" valign="bottom">NCBI</td><td align="left" valign="bottom">Gene ID: 11865</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Gene (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Cry1</italic></td><td align="left" valign="bottom">NCBI</td><td align="left" valign="bottom">Gene ID: 12952</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Gene (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Cry2</italic></td><td align="left" valign="bottom">NCBI</td><td align="left" valign="bottom">Gene ID: 12953</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Gene (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>P2ry1</italic></td><td align="left" valign="bottom">NCBI</td><td align="left" valign="bottom">Gene ID: 18441</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Strain (<italic>M. musculus</italic>), strain background (<italic>C57BL6J</italic>)</td><td align="left" valign="bottom"><italic>PdxCre;Bmal1<sup>flx/flx</sup></italic></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/20562852/">20562852</ext-link></td><td align="left" valign="bottom"><italic>PdxCre;Bmal1<sup>flx/flx</sup></italic></td><td align="left" valign="bottom">Pancreas-specific <italic>Bmal1</italic> mutant mice</td></tr><tr><td align="left" valign="bottom">Strain (<italic>M. musculus</italic>), strain background (<italic>C57BL6J</italic>)</td><td align="left" valign="bottom"><italic>Cry1<sup>-/-</sup></italic>;<italic>Cry2<sup>-/-</sup></italic></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/10518585/">10518585</ext-link></td><td align="left" valign="bottom"><italic>Cry1<sup>-/-</sup></italic>;<italic>Cry2<sup>-/-</sup></italic></td><td align="left" valign="bottom">Whole-body <italic>Cry1</italic> and <italic>Cry2</italic> double knockout mice</td></tr><tr><td align="left" valign="bottom">Strain (<italic>M. musculus</italic>), strain background (<italic>C57BL6J</italic>)</td><td align="left" valign="bottom">C57BL/6-<italic>Ins2<sup>Akita</sup></italic>/J</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="char" char="." valign="bottom">3548</td><td align="left" valign="bottom">Spontaneous mutation in the insulin two gene leads to incorrect folding of the insulin protein<break/>Monogenic mouse model for type 1 diabetes.</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Primary pancreatic islets</td><td align="left" valign="bottom">Northwestern University</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Freshly isolated from mice</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Primary pancreatic islets</td><td align="left" valign="bottom">Alberta Diabetes Institute Islet-Core</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.isletcore.ca">https://www.isletcore.ca</ext-link> (R224, R225, R226)</td><td align="left" valign="bottom">Freshly isolated from nondiabetic donors</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">HEK293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-11268</td><td align="left" valign="bottom">Kidney cells</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Beta-TC-6</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-11506</td><td align="left" valign="bottom">Pancreatic β-cells</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Bmal1<sup>-/-</sup></italic> Beta-TC-6</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/21686102/">21686102</ext-link></td><td align="left" valign="bottom"><italic>Bmal1<sup>-/-</sup></italic> Beta-TC-6</td><td align="left" valign="bottom">Pancreatic β-cells, mutant for <italic>Bmal1</italic></td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Insulin-NanoLuc-expressing Beta-TC-6</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Pancreatic β-cells, expressing Proinsulin-NanoLuc luminescent reporter</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Insulin-NanoLuc-expressing <italic>Bmal1<sup>-/-</sup></italic> Beta-TC-6</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Pancreatic β-cells, mutant for <italic>Bmal1</italic>, expressing Proinsulin-NanoLuc luminescent reporter</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">P2Y1 CRISPR/Cas9 KO plasmid</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">sc-422095</td><td align="left" valign="bottom">Pool of three plasmids, encoding the Cas9 nuclease and a P2Y1-specific 20 nt guide RNA, targeting exon 1 of the mouse <italic>P2ry1</italic> gene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">P2Y1 HDR plasmid</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">sc-422095-HDR</td><td align="left" valign="bottom">Pool of 2–3 plasmids, containing puromycin resistance gene and HDR templates, corresponding to the P2Y1 CRISPR/Cas9 KO plasmid cut sites</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Proinsulin-NanoLuc in pLX304 lentivirus packaging plasmid</td><td align="left" valign="bottom">Addgene</td><td align="char" char="." valign="bottom">62057</td><td align="left" valign="bottom">Luminescent reporter of insulin secretion, mouse synthetic Ins2 insert</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCMV-VSV-G</td><td align="left" valign="bottom">Addgene</td><td align="char" char="." valign="bottom">8454</td><td align="left" valign="bottom">Envelope vector</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCMV delta R8.2</td><td align="left" valign="bottom">Addgene</td><td align="char" char="." valign="bottom">12263</td><td align="left" valign="bottom">Packaging vector</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Spectrum Collection</td><td align="left" valign="bottom">MicroSource Discovery Systems, Inc</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Small-molecule compound library, which consists of 2640 known drugs and drug-like molecules</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ivermectin</td><td align="left" valign="bottom">Tocris</td><td align="char" char="." valign="bottom">1260</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">(+)-Bicuculline</td><td align="left" valign="bottom">Tocris</td><td align="char" char="." valign="bottom">130</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">MRS2179 tetrasodium salt</td><td align="left" valign="bottom">Tocris</td><td align="char" char="." valign="bottom">900</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Isradipine</td><td align="left" valign="bottom">Cayman Chemical Company</td><td align="char" char="." valign="bottom">17536</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Phorbol 12-myristate 13-acetate (PMA)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">P1585</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Carbamoylcholine chloride</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">C4382-1G</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Forskolin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">F3917-10MG</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">D-Glucose</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">G7528-250G</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Potassium chloride</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">P-5405</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">3-Isobutyl-1-methylxanthine</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">I7018-250mg</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Tyrothricin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">T3000000</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Alexidine hydrochloride</td><td align="left" valign="bottom">Cayman Chemical Company</td><td align="char" char="." valign="bottom">13876</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Benzalkonium chloride</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="char" char="." valign="bottom">12060-5G</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Suloctidil</td><td align="left" valign="bottom">MicroSource Discovery Systems, Inc</td><td align="char" char="." valign="bottom">01501153</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Tomatine</td><td align="left" valign="bottom">MicroSource Discovery Systems, Inc</td><td align="char" char="." valign="bottom">01504079</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Isoetharine mesylate</td><td align="left" valign="bottom">MicroSource Discovery Systems, Inc</td><td align="char" char="." valign="bottom">01505977</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Tacrine hydrochloride</td><td align="left" valign="bottom">MicroSource Discovery Systems, Inc</td><td align="char" char="." valign="bottom">02300104</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Pipamperone</td><td align="left" valign="bottom">MicroSource Discovery Systems, Inc</td><td align="char" char="." valign="bottom">01505690</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dyclonine hydrochloride</td><td align="left" valign="bottom">MicroSource Discovery Systems, Inc</td><td align="char" char="." valign="bottom">01500268</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Desoxycorticosterone acetate</td><td align="left" valign="bottom">MicroSource Discovery Systems, Inc</td><td align="char" char="." valign="bottom">00300029</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Puromycin dihydrochloride</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">P8833-25MG</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Collagenase P</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">C7657-100mg</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Biocoll</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">L6155</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">2-Hydroxypropyl-b-cyclodextrin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">H107-5G</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Fura-2</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">F1201</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Pluronic F-127</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">P3000MP</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Penicillin-streptomycin</td><td align="left" valign="bottom">Gibco</td><td align="char" char="hyphen" valign="bottom">15-140-122</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">L-glutamine</td><td align="left" valign="bottom">Gibco</td><td align="char" char="hyphen" valign="bottom">25-030-081</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Lipofectamine 3000</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">L3000015</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NanoGlo Luciferase Assay Substrate</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">N1110</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Ultra Sensitive Mouse Insulin ELISA Kit</td><td align="left" valign="bottom">Crystal Chem Inc</td><td align="char" char="." valign="bottom">90080</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Autokit Glucose</td><td align="left" valign="bottom">Wako-Fujifilm</td><td align="char" char="." valign="bottom">997-03001</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Direct-zol RNA Microprep kit</td><td align="left" valign="bottom">Zymo Research</td><td align="left" valign="bottom">R2062</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">High Capacity cDNA Reverse Transcription Kit</td><td align="left" valign="bottom">Applied Biosystems</td><td align="char" char="." valign="bottom">4368813</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">iTaq Universal SYBR Green Supermix</td><td align="left" valign="bottom">Applied Biosystems</td><td align="char" char="." valign="bottom">1725125</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NEBNext Ultra Directional RNA Library Prep Kit for Illumina</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">E7760L</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NEBNext Library Quant Kit for Illumina</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">E7630L</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Quick Start Bradford Protein Assay</td><td align="left" valign="bottom">Bio-Rad</td><td align="char" char="." valign="bottom">500-0116</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>β-actin</italic> F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">5′-TGCTCTGGCTCCTAGCACCATGAAGATCAA-3′</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>β-actin</italic> R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">5′-AAACGCAGCTCAGTAACAGTCCGCCTAGAA-3′</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>P2ry1</italic> F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">5′-TTATGTCAGCGTGCTGGTGT-3′</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>P2ry1</italic> R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">5′-ACGTGGTGTCATAGCAGGTG-3′</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-P2Y1, mouse monoclonal</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">sc-377324</td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-β-ACTIN, rabbit monoclonal</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">CST 4970</td><td align="left" valign="bottom">WB (1:4000)</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">STAR</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/23104886/">23104886</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_004463">SCR_004463</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">RSEM</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/21816040/">21816040</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_013027">SCR_013027</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">DESeq2 package in R</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25516281/">25516281</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_015687">SCR_015687</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Pheatmap package in R</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016418">SCR_016418</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">SRA-Toolkit</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://trace.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?view=software">https://trace.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?view=software</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Seurat in package in R</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/34062119/">34062119</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_007322">SCR_007322</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">JTK_Cycle</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/20876817/">20876817</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_017962">SCR_017962</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Dulbecco’s modified Eagle’s medium</td><td align="left" valign="bottom">Gibco</td><td align="char" char="." valign="bottom">90-013-pb</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Fetal bovine serum</td><td align="left" valign="bottom">Bio-Techne</td><td align="left" valign="bottom">S11550</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">RIPA buffer</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">R0278-50ML</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Tri Reagent</td><td align="left" valign="bottom">Molecular Research Center, Inc</td><td align="left" valign="bottom">NC9277980</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Complete Mini EDTA-Free Protease Inhibitor</td><td align="left" valign="bottom">Roche</td><td align="char" char="." valign="bottom">4693159001</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">PhoStop</td><td align="left" valign="bottom">Roche</td><td align="char" char="." valign="bottom">4906837001</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Nitrocellulose membranes</td><td align="left" valign="bottom">Bio-Rad</td><td align="char" char="." valign="bottom">1620112</td><td align="left" valign="bottom"> </td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Reagents</title><p>IVM, (+)-bicuculline, and MRS2179 tetrasodium salt were obtained from Tocris (R&amp;D Systems, Inc, Minneapolis, MN). Isradipine and alexidine hydrochloride were purchased from Cayman Chemical Company (Ann Arbor, MI). PMA, carbamoylcholine chloride (carbachol), forskolin, tyrothricin, and benzalkonium chloride were obtained from Sigma-Aldrich (St. Louis, MO). Suloctidil, tomatine, isoetharine mesylate, tacrine hydrochloride, pipamperone, dyclonine hydrochloride, and desoxycorticosterone acetate were purchased from MicroSource Discovery Systems, Inc.</p></sec><sec id="s4-2"><title>Animals</title><p>Male WT C57BL6J mice and C57BL/6-<italic>Ins2<sup>Akita</sup></italic>/J mice were purchased from the Jackson Laboratory (Bar Harbor, ME). <italic>PdxCre;Bmal1<sup>flx/flx</sup></italic> and <italic>Cry1<sup>-/-</sup>;Cry2<sup>-/-</sup></italic> mice were produced and maintained on C57BL6J background at the Northwestern University Center for Comparative Medicine (Protocols IS00000466, IS00003253, IS00008732, IS0005838) (<xref ref-type="bibr" rid="bib60">Peek et al., 2013</xref>; <xref ref-type="bibr" rid="bib81">Vitaterna et al., 1999</xref>). Unless otherwise stated, animals were maintained on a 12:12 light:dark cycle and allowed free access to water and regular chow. All animal care and use procedures were conducted in accordance with regulation of the Institutional Animal Care and Use Committee at Northwestern University.</p></sec><sec id="s4-3"><title>Cell culture</title><p>Beta-TC-6 cells were obtained from ATCC (Manassas, VA) (CRL-11506), and <italic>Bmal1<sup>-/-</sup></italic> Beta-TC-6 β-cell lines were previously derived as described (<xref ref-type="bibr" rid="bib52">Marcheva et al., 2020</xref>). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Aramillo, TX) supplemented with 15% fetal bovine serum (Bio-Techne, Minneapolis, MN), 1% penicillin-streptomycin (Gibco), and 1% L-glutamine (Gibco) at 37°C with 5% CO<sub>2</sub>. Culture medium was exchanged every 2–3 days. All cells used in experiments were at &lt;15 passages. Cells were routinely checked for mycoplasma contamination.</p></sec><sec id="s4-4"><title>Generation of WT and <italic>Bmal1<sup>-/-</sup></italic> Beta-TC-6 cells stably expressing insulin-NanoLuc</title><p>We used the proinsulin-NanoLuc plasmid (David Altshuler, Addgene plasmid #62057, proinsulin-NanoLuc in pLX304) to provide a low-cost, scalable, and rapid method to detect insulin secretion. The gene encoding NanoLuc was cloned into the C-peptide portion of mouse proinsulin such that cleavage within insulin vesicles by pH-sensitive prohormone convertase results in the co-secretion of NanoLuc with endogenous insulin in a stimulus-dependent manner (<xref ref-type="bibr" rid="bib7">Burns et al., 2015</xref>). The pLX304 lentivirus packaging plasmid containing the proinsulin-NanoLuc construct was transfected into HEK293T (ATCC CRL-11268) cells with pCMV-VSVG (envelope vector, Addgene plasmid #8454) and pCMV delta R8.2 (packaging vector, Addgene plasmid #12263). Supernatant containing lentivirus particles was harvested 48 hr after transfection. Beta-TC-6 and <italic>Bmal1<sup>-/-</sup></italic> Beta-TC-6 cells were infected with insulin-NanoLuc lentivirus, and stably expressing cells were selected by treating with puromycin (2 µg/ml, 2 days).</p></sec><sec id="s4-5"><title>CRISPR-mediated <italic>P2ry1</italic> deletion in WT and <italic>Bmal1<sup>-/-</sup></italic> Beta-TC-6 cells</title><p>Exon 1 of the mouse <italic>P2yr1</italic> gene was deleted in WT and <italic>Bmal1<sup>-/-</sup></italic> Beta-TC-6 cells by CRISPR-Cas9 and homology-directed repair (HDR). Cells were co-transfected with guide RNA, P2Y1 CRISPR/Cas9 KO, and P2Y1 HDR plasmids (Santa Cruz Biotechnology, Dallas, TX, sc-422095 and sc-422095-HDR) by Lipofectamine 3000 (Thermo Fisher Scientific, Amarillo, TX). The locations of the three sites targeted for ablation by the P2Y1 CRISPR/Cas9 KO plasmids are indicated in <xref ref-type="fig" rid="fig4">Figure 4A</xref>. After 48 hr of transfection, stably integrated clones were selected for puromycin resistance (puromycin dihydrochloride, Sigma-Aldrich). RNA and protein were extracted from these colonies, and <italic>P2ry1</italic> expression was assessed by qPCR and Western blot.</p></sec><sec id="s4-6"><title>High-throughput screen for drugs to restore insulin secretion in <italic>Bmal1<sup>-/-</sup></italic> β-cells and insulin secretion assays</title><p>The Spectrum Collection small-molecule compound library (MicroSource Discovery Systems, Inc), which consists of 2640 known drugs and drug-like molecules, was screened for compounds that augment insulin secretion in <italic>Bmal1<sup>-/-</sup></italic> Beta-TC-6 cells. Insulin-NanoLuc-expressing <italic>Bmal1<sup>-/-</sup></italic> Beta-TC-6 cells (40,000 cells/well) were placed into 384-well plates and cultured for 3 days at 37°C and 5% CO<sub>2</sub>. The cells were washed once and incubated in KRB buffer containing 0 mM glucose for 1 hr. Then, KRB buffer containing 20 mM glucose in addition to the small molecules (10 µM) were added, and the cells were incubated for 1 hr. As a negative control, 16 wells received KRB buffer with only 20 mM glucose, which fails to elicit appropriate insulin secretion in <italic>Bmal1<sup>-/-</sup></italic> cells, and as a positive control, 16 wells received KRB buffer containing 20 mM glucose and 10 μM PMA, which is known to induce insulin secretion in both <italic>Bmal1<sup>-/-</sup></italic> mouse islets and Beta-TC-6 cells (<xref ref-type="bibr" rid="bib61">Perelis et al., 2015</xref>). After 1 hr, the supernatant was collected and centrifuged at 500 × <italic>g</italic> for 30 min. The supernatant was transferred into a fresh 384-well assay plate containing NanoGlo Luciferase Assay Substrate (Promega, Madison, WI), and luciferase intensity was measured by EnSpire Plate Reader (PerkinElmer, Waltham, MA) within 30 min. All liquids for the high-throughput screen were dispensed using Tecan Fluent Automated Liquid Handling Platform (Tecan, Mannedorf, Switzerland) at the High-Throughput Analysis Laboratory at Northwestern University. Screen feasibility was determined by calculating Z'-factor using the following formula: Z'-factor = 1–3(σ<sub>p</sub> + σ<sub>n</sub>)/(μ<sub>p</sub> - μ<sub>n</sub>) (where σ<sub>p</sub> is the standard deviation of positive control [20 mM glucose + PMA], σ<sub>n</sub> is the standard deviation of negative control [20 mM glucose only], μ<sub>p</sub> is the mean intensity of positive control, and μ<sub>n</sub> is the mean intensity of the negative control) (<xref ref-type="bibr" rid="bib85">Zhang et al., 1999</xref>).</p></sec><sec id="s4-7"><title>Determination of hit compounds</title><p>Z-scores are a measure of how many standard deviations above or below the population mean a raw score is. Z-scores for luciferase intensities produced by screened compounds were calculated from the following formula: z = (X – μ)/σ (where z is the Z-score, X is the luciferase intensity of the compounds, μ is the intensity of negative control [20 mM glucose], and σ is the standard deviation of negative control). A row-based correction factor was applied to all luciferase readings to adjust for logarithmic signal decay. Hit compounds were defined as those that elicited a response of greater than 3 standard deviations from the mean (Z-score &gt; 3) and more than 1.25-fold increase compared to negative control, which is the cutoff for ~10% chance of the observation occurring by random chance. Validated hit compounds that augmented insulin secretion at low drug dose were considered lead compounds.</p></sec><sec id="s4-8"><title>Insulin secretion assays in pancreatic islets, pseudoislets, and cell lines</title><p>Mouse pancreatic islets were isolated via bile duct collagenase digestion (<italic>Collagenase P</italic>, Sigma) and Biocoll (Millipore) gradient separation and left to recover overnight at 37°C in RPMI 1640 with 10% FBS, 1% L-glutamine, and 1% penicillin/streptomycin. For insulin release assays, duplicates of five equally sized islets per mouse were statically incubated in Krebs-Ringer Buffer (KRB) at 2 mM glucose for 1 hr and then stimulated for 1 hr at 37°C with 2 mM or 20 mM glucose in the presence or absence of 10 μM of each compound. Supernatant was collected and assayed for insulin content by ELISA (Crystal Chem Inc, Elk Grove Village, IL). Islets were then sonicated in acid-ethanol solution and solubilized overnight at 4°C before assaying total insulin content by ELISA. For insulin release assays from pseudoislets, 3 × 10<sup>6</sup> cells were plated for 3 days in 60 mm suspension dishes and allowed to form pseudoislets for 2–3 days. Glucose-responsive insulin secretion was performed as described above using 10 pseudoislets per sample and a basal glucose level of 0 mM glucose instead of 2 mM (<xref ref-type="bibr" rid="bib52">Marcheva et al., 2020</xref>). For secretion from insulin-NanoLuc cell lines, 1 × 10<sup>5</sup> cells were cultured on poly-L-lysine-coated 96 well plates for 2–3 days, starved for 1 hr in 0 mM glucose KRB, then stimulated with indicated compounds and/or receptor antagonists for 1 hr in conjunction with 0 mM basal glucose or 20 mM stimulatory glucose conditions. Luciferase intensity after addition of NanoGlo to supernatant was measured by Cytation3 Plate Reader (BioTek, Winooski, VT).</p></sec><sec id="s4-9"><title>Perifusion of primary islets and pseudoislets</title><p>Primary islets from <italic>PdxCre;Bmal1<sup>flx/flx</sup></italic> and <italic>Bmal1<sup>flx/flx</sup></italic> mice were isolated as described above and left to recover overnight. Perifusion of 100 islets per mouse per treatment was performed using a Biorep Technologies Perifusion System Model PERI-4.2 with a rate of 100 μl/min KRB (0.1% BSA). After 1 hr of preincubation and equilibration at a rate of 100 μl/min with 2 mM glucose KRB, islets were perifused for 10 min with 2 mM glucose KRB, followed by perifusion for 30 min with 20 mM glucose or 20 mM glucose plus IVM. Perifusate was collected in 96-well plates, and insulin secreted was analyzed via ELISA. Perifusion of insulin-NanoLuc pseudoislets was performed in an identical manner using 0 mM glucose KRB instead of 2 mM glucose KRB. Pseudoislet perifusate was analyzed for NanoLuc activity using NanoGlo Luciferase Assay Substrate (Promega) as per the manual instructions.</p></sec><sec id="s4-10"><title>In vivo ivermectin treatment and glucose measurements</title><p>Mice were injected intraperitoneally for 14 days with 1.3 mg/kg body weight of IVM, which was dissolved in 40% w/v 2-hydroxypropyl-β-cyclodextrin (Sigma-Aldrich) (<xref ref-type="bibr" rid="bib36">Jin et al., 2013</xref>). At the end of IVM treatment, mice were fasted for 14 hr and glucose tolerance tests were performed at ZT2 following intraperitoneal glucose injection at 2 g/kg body weight. Plasma glucose levels were measured by enzymatic assay (Autokit Glucose, Wako-Fujifilm, Cincinnati, OH).</p></sec><sec id="s4-11"><title>Synchronization, RNA isolation, and qPCR mRNA quantification</title><p>Where indicated, circadian synchronization was performed using 200 WT pseudoislets by first exposing cells to 10 μM forskolin for 1 hr, followed by transfer to normal media and RNA collection every 4 hr 24–44 hr following forskolin synchronization pulse. RNA was extracted from Beta-TC-6 cells and pseudoislets using Tri Reagent (Molecular Research Center, Inc, Cincinnati, OH) and frozen at −80°C. RNA was purified according to the manufacturer’s protocol using the Direct-zol RNA Microprep kit (Zymo Research, Irvine, CA) with DNase digestion. cDNAs were then synthesized using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Amarillo, TX). Quantitative real-time PCR analysis was performed with SYBR Green Master Mix (Applied Biosystems) and analyzed using a Touch CFX384 Real-Time PCR Detection System (Bio-Rad, Hercules, CA). Target gene expression levels were normalized to <italic>β-actin</italic> and set relative to control conditions using the comparative C<sub>T</sub> method. Primer sequences for qPCR are as follows: <italic>β-actin</italic> forward: 5'-<named-content content-type="sequence">TGCTCTGGCTCCTAGCACCATGAAGATCAA</named-content>-3', reverse: 5'-<named-content content-type="sequence">AAACGCAGCTCAGTAACAGTCCGCCTAGAA</named-content>-3'; <italic>P2ry1</italic> forward: 5'- <named-content content-type="sequence">TTATGTCAGCGTGCTGGTGT</named-content>-3', reverse: 5'-<named-content content-type="sequence">ACGTGGTGTCATAGCAGGTG</named-content>-3'.</p></sec><sec id="s4-12"><title>RNA-sequencing and analysis</title><p>Following RNA isolation (described above), RNA quality was assessed using a Bioanalyzer (Agilent, Santa Clara, CA), and sequencing libraries were constructed using a NEBNext Ultra Directional RNA Library Prep Kit for Illumina (New England Biolabs, Ipswich, MA, E7420L) according to the manufacturer’s instructions. Libraries were quantified using a NEBNext Library Quant Kit for Illumina (New England Biolabs, E7630L) and sequenced on an Illumina NextSeq 500 instrument using 42 bp paired-end reads. For differential expression analysis, RNA raw sequence reads were aligned to the reference genome (mm10) using STAR version 2.7.2b, and raw and transcripts per million (TPM) count values determined using RSEM version 1.3.3. Differentially expressed RNAs were identified by a false discovery rate (FDR)-adjusted p-value&lt;0.05 and a fold change &gt; 1.5 using DESeq2 version 1.32.0 in R 4.1.0. Heatmaps were generated using the pheatmap package in R. Raw mRNA sequencing data and gene abundance measurements have been deposited in the Gene Expression Omnibus under accession GSE186469.</p></sec><sec id="s4-13"><title>Intracellular calcium determination</title><p>Beta-TC-6 cells were plated at a density of 100,000 cells per well in black 96-well plates with clear bottoms and cultured overnight at 37°C and 5% CO<sub>2</sub>. Cells were then washed with BSA-free KRB buffer with no glucose and loaded with 5 μM Fura-2 (Invitrogen, Amarillo, TX) and 0.04% Pluronic F-127 (Invitrogen) for 30 min at 37°C. Following a wash with BSA-free KRB, Fura-2 intensity was measured after stimulation with either glucose alone or glucose plus the indicated compounds. Cells were alternately excited with 340 nm and 380 nm wavelength light, and the emitted light was detected at 510 nm using a Cytation 3 Cell Imaging Multi-Mode Reader (BioTek) at sequential 30 s intervals. Raw fluorescence data were exported to Microsoft Excel and expressed as the 340/380 ratio for each well.</p></sec><sec id="s4-14"><title>Human islet studies and ethics statement</title><p>Human islet isolations and human islet cell biology experiments approved by the University of Alberta Human Research Ethics Board (approval identifiers: Pro00013094; Pro00001754) were performed at the Alberta Diabetes Institute Islet-Core according to the methods deposited in the <ext-link ext-link-type="uri" xlink:href="http://protocols.io/">protocols.io</ext-link> repository (<xref ref-type="bibr" rid="bib35">Isolation of Human Pancreatic Islets of Langerhans for Research V.3, 2021</xref>). Organ donation was coordinated by the appropriate regional organ procurement organization, including obtaining written next-of-kin consent for use of donor organs in this study. Donor organs were deidentified by the organ procurement organization prior to shipment to the Alberta Diabetes Institute Islet-Core, and no identifying donor information was made available to the research team. A total of three nondiabetic (ND) donors were examined in this study. Full details of donor information, organ processing, and quality control information can be assessed with donor number (donors R224, R225, and R226 in this study) at <ext-link ext-link-type="uri" xlink:href="https://www.isletcore.ca">https://www.isletcore.ca</ext-link>.</p></sec><sec id="s4-15"><title>Patch-clamp electrophysiology in human and mouse islets</title><p>Patch-clamp measurement of exocytic responses in mouse β-cells was performed as previously described (<xref ref-type="bibr" rid="bib52">Marcheva et al., 2020</xref>). Dispersed human islets were cultured in low glucose (5.5 mM) DMEM media (supplemented with L-glutamine, 110 mg/l sodium pyruvate, 10% FBS, and 100 U/ml penicillin/streptomycin) in 35 mm culture dishes overnight. On the day of patch-clamp measurements, human or mouse islet cells were preincubated in extracellular solution at 1 mM glucose for 1 hr and capacitance was measured at 10 mM glucose with DMSO or 10 µM IVM as previously described (<xref ref-type="bibr" rid="bib52">Marcheva et al., 2020</xref>). Mouse β-cells were identified by cell size and by half-maximal inactivation of Na<sup>+</sup> currents near –90 mV, and human β-cells were identified by immunostaining for positive insulin, following the experiment as described (<xref ref-type="bibr" rid="bib20">Fu et al., 2019</xref>). Data analysis was performed using GraphPad Prism (v8.0c). Comparison of multiple groups was done by one- or two-way ANOVA, followed by Bonferroni or Tukey’s post test. Data are expressed as means ± SEM, where p&lt;0.05 is considered significant.</p></sec><sec id="s4-16"><title>Single-cell RNA-seq analysis</title><p>Sequencing data from the study under SRA accession ERP017126 (<xref ref-type="bibr" rid="bib75">Segerstolpe et al., 2016</xref>) were downloaded and converted to fastq files using the commands ‘prefetch’ followed by ‘fastq-dump’ through the sra-toolkit (v2.10.5). Each individual cell was aligned and transcript abundance quantified using RSEM with Hg38 (GRCh38.p12) as a reference. Raw single-cell expression count values were imported into RStudio for analysis using Seurat (<xref ref-type="bibr" rid="bib28">Hao et al., 2021</xref>). Following low-quality cell removal, normalized expression values were used in uniform manifold approximation and projection (UMAP) dimensional reduction analyses to cluster distinct cell types. The R script, raw count tables, and parameters of these analyses are made publicly available under the Gene Expression Omnibus accession GSE186469.</p></sec><sec id="s4-17"><title>Western blotting</title><p>Beta-TC-6 cells lysates were isolated by treating cell pellets with RIPA buffer (Sigma-Aldrich) supplemented with 1× protease and 1× phosphatase inhibitors (Roche, Basel, Switzerland). Protein levels were quantified using Quick Start Bradford Protein Assay, and protein extracts were subject to SDS-PAGE gel electrophoresis and transferred to nitrocellulose membranes (Bio-Rad). Primary antibodies used were anti-P2Y1 (Santa Cruz, sc-377324) and anti-β-actin (Cell Signaling, Danvers, MA, CST 4970).</p></sec><sec id="s4-18"><title>Statistical analysis</title><p>Results were expressed as mean ± SEM unless otherwise noted. Information on sample size, genotype, and p values is provided within each figure and figure legend. Statistical significance of capacitance, Fura2, and perifusion data was performed using a two-way ANOVA or mixed effects model (for datasets with missing values) with repeated measures followed by multiple comparison tests using a Bonferroni p-value adjustment via Prism (v9.2.0). Statistical analysis was performed by unpaired two-tailed Student’s <italic>t</italic>-test unless otherwise indicated. p&lt;0.05 was considered statistically significant. JTK_Cycle (v3) was used to determine rhythmicity in qPCR data using a period length of 24 hr and considering a Benjamini–Hochberg (BH)-adjusted p-value&lt;0.05 as statistically rhythmic (<xref ref-type="bibr" rid="bib33">Hughes et al., 2010</xref>).</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Mark Perelis is affiliated with Ionis Pharmaceuticals, Inc The author has no financial interests to declare</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Investigation, Methodology, Supervision, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con10"><p>Formal analysis, Funding acquisition, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Formal analysis, Funding acquisition, Investigation, Methodology, Supervision, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human islet isolations and human islet cell biology experiments were performed at the Alberta Diabetes Institute IsletCore and approved by the University of Alberta Human Research Ethics Board (approval identifiers: Pro00013094, Pro00001754). Organ donation was coordinated by the appropriate regional organ procurement organization, including obtaining written next-of-kin consent for use of donor organs in this study. Donor organs were de-identified by the organ procurement organization prior to shipment to the Alberta Diabetes Institute IsletCore, and no identifying donor information was made available to the research team.</p></fn><fn fn-type="other"><p>All animal care and use procedures were conducted in accordance with regulation of the Institutional Animal Care and Use Committee at Northwestern University under protocols IS00000466, IS00003253, IS00008732, IS0005838.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>High-throughput screen results.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-75132-supp1-v1.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Results of differential expression analysis in ivermectin (IVM)-treated WT and <italic>P2ry1</italic><sup>-/-</sup>β cells.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-75132-supp2-v1.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-75132-transrepform1-v1.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Data in this study is publicly available in the GEO repository GSE186469. Source data files have been provided for the compounds used in the screen (Table S1), RNA-seq results (Table S2), and gel images (Source Data 1-2).</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Weidemann</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>High-throughput screen reveals purinergic receptor as a therapeutic target in circadian β-cell failure</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE186469">GSE186469</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Perelis</surname><given-names>M</given-names></name><name><surname>Marcheva</surname><given-names>B</given-names></name><name><surname>Barish</surname><given-names>GD</given-names></name><name><surname>Bass</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><data-title>Genome-wide Circadian Control of Transcription at Active Enhancers Regulates Insulin Secretion and Diabetes Risk</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69889">GSE69889</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Perelis</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>A role for alternative splicing in circadian control of insulin secretion and glucose homeostasis</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE146916">GSE146916</pub-id></element-citation></p><p><element-citation id="dataset4" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Palasantza</surname><given-names>A</given-names></name><name><surname>Sandberg</surname><given-names>R</given-names></name><name><surname>Segerstolpe</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><data-title>Single-cell RNA-seq analysis of human pancreas from healthy individuals and type 2 diabetes patients</data-title><source>ArrayExpress</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-5061/">E-MTAB-5061</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank all members of the Bass laboratory, Dr. Grant Barish, Dr. Lisa Beutler, and Dr. Richard Miller for helpful discussions and comments on the manuscript. We also thank Shun Kobayashi for technical assistance and Dr. Clara Bien Peek for the <italic>Cry1<sup>-/-</sup>;Cry2<sup>-/-</sup></italic> mice. We thank the Human Organ Procurement and Exchange (HOPE) program and Trillium Gift of Life Network (TGLN) for their work in procuring human donor pancreas for research. Finally, we especially thank the organ donors and their families for their kind gift in support of diabetes research.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez-Dominguez</surname><given-names>JR</given-names></name><name><surname>Donaghey</surname><given-names>J</given-names></name><name><surname>Rasouli</surname><given-names>N</given-names></name><name><surname>Kenty</surname><given-names>JHR</given-names></name><name><surname>Helman</surname><given-names>A</given-names></name><name><surname>Charlton</surname><given-names>J</given-names></name><name><surname>Straubhaar</surname><given-names>JR</given-names></name><name><surname>Meissner</surname><given-names>A</given-names></name><name><surname>Melton</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Circadian Entrainment Triggers Maturation of Human In Vitro Islets</article-title><source>Cell Stem Cell</source><volume>26</volume><fpage>108</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2019.11.011</pub-id><pub-id pub-id-type="pmid">31839570</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arrojo E Drigo</surname><given-names>R</given-names></name><name><surname>Roy</surname><given-names>B</given-names></name><name><surname>MacDonald</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Molecular and functional profiling of human islets: from heterogeneity to human phenotypes</article-title><source>Diabetologia</source><volume>63</volume><fpage>2095</fpage><lpage>2101</lpage><pub-id pub-id-type="doi">10.1007/s00125-020-05159-8</pub-id><pub-id pub-id-type="pmid">32894320</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balasubramanian</surname><given-names>R</given-names></name><name><surname>Ruiz de Azua</surname><given-names>I</given-names></name><name><surname>Wess</surname><given-names>J</given-names></name><name><surname>Jacobson</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Activation of distinct P2Y receptor subtypes stimulates insulin secretion in MIN6 mouse pancreatic beta cells</article-title><source>Biochemical Pharmacology</source><volume>79</volume><fpage>1317</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2009.12.026</pub-id><pub-id pub-id-type="pmid">20067775</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berjukow</surname><given-names>S</given-names></name><name><surname>Marksteiner</surname><given-names>R</given-names></name><name><surname>Gapp</surname><given-names>F</given-names></name><name><surname>Sinnegger</surname><given-names>MJ</given-names></name><name><surname>Hering</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Molecular mechanism of calcium channel block by isradipine. Role of a drug-induced inactivated channel conformation</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>22114</fpage><lpage>22120</lpage><pub-id pub-id-type="doi">10.1074/jbc.M908836199</pub-id><pub-id pub-id-type="pmid">10766758</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bierman</surname><given-names>CW</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Adrenergic drugs</article-title><source>Clinical Reviews in Allergy</source><volume>1</volume><fpage>87</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1007/BF02991319</pub-id><pub-id pub-id-type="pmid">6142760</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowler</surname><given-names>JW</given-names></name><name><surname>Bailey</surname><given-names>RJ</given-names></name><name><surname>North</surname><given-names>RA</given-names></name><name><surname>Surprenant</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>P2X4, P2Y1 and P2Y2 receptors on rat alveolar macrophages</article-title><source>British Journal of Pharmacology</source><volume>140</volume><fpage>567</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0705459</pub-id><pub-id pub-id-type="pmid">12970084</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>SM</given-names></name><name><surname>Vetere</surname><given-names>A</given-names></name><name><surname>Walpita</surname><given-names>D</given-names></name><name><surname>Dančík</surname><given-names>V</given-names></name><name><surname>Khodier</surname><given-names>C</given-names></name><name><surname>Perez</surname><given-names>J</given-names></name><name><surname>Clemons</surname><given-names>PA</given-names></name><name><surname>Wagner</surname><given-names>BK</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>High-throughput luminescent reporter of insulin secretion for discovering regulators of pancreatic Beta-cell function</article-title><source>Cell Metabolism</source><volume>21</volume><fpage>126</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2014.12.010</pub-id><pub-id pub-id-type="pmid">25565210</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrano</surname><given-names>AC</given-names></name><name><surname>Mulas</surname><given-names>F</given-names></name><name><surname>Zeng</surname><given-names>C</given-names></name><name><surname>Sander</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Interrogating islets in health and disease with single-cell technologies</article-title><source>Molecular Metabolism</source><volume>6</volume><fpage>991</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1016/j.molmet.2017.04.012</pub-id><pub-id pub-id-type="pmid">28951823</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Changeux</surname><given-names>JP</given-names></name><name><surname>Ryter</surname><given-names>A</given-names></name><name><surname>Leuzinger</surname><given-names>W</given-names></name><name><surname>Barrand</surname><given-names>P</given-names></name><name><surname>Podleski</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1969">1969</year><article-title>On the association of tyrocidine with acetylcholinesterase</article-title><source>PNAS</source><volume>62</volume><fpage>986</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1073/pnas.62.3.986</pub-id><pub-id pub-id-type="pmid">5257018</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatelain</surname><given-names>P</given-names></name><name><surname>Demol</surname><given-names>D</given-names></name><name><surname>Roba</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Inhibition by suloctidil of [3H] nitrendipine binding to cerebral cortex membranes</article-title><source>Biochemical Pharmacology</source><volume>33</volume><fpage>1099</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(84)90520-3</pub-id><pub-id pub-id-type="pmid">6324812</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Yoo</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Buhr</surname><given-names>E</given-names></name><name><surname>Ye</surname><given-names>ZY</given-names></name><name><surname>Pan</surname><given-names>HL</given-names></name><name><surname>Takahashi</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Identification of diverse modulators of central and peripheral circadian clocks by high-throughput chemical screening</article-title><source>PNAS</source><volume>109</volume><fpage>101</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1073/pnas.1118034108</pub-id><pub-id pub-id-type="pmid">22184224</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>IS</given-names></name><name><surname>Kubo</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Ivermectin and its target molecules: shared and unique modulation mechanisms of ion channels and receptors by ivermectin</article-title><source>The Journal of Physiology</source><volume>596</volume><fpage>1833</fpage><lpage>1845</lpage><pub-id pub-id-type="doi">10.1113/JP275236</pub-id><pub-id pub-id-type="pmid">29063617</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crismon</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Tacrine: first drug approved for Alzheimer’s disease</article-title><source>The Annals of Pharmacotherapy</source><volume>28</volume><fpage>744</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1177/106002809402800612</pub-id><pub-id pub-id-type="pmid">7919566</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>GR</given-names></name><name><surname>Wafford</surname><given-names>KA</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Marshall</surname><given-names>GR</given-names></name><name><surname>Bayley</surname><given-names>PJ</given-names></name><name><surname>Schaeffer</surname><given-names>JM</given-names></name><name><surname>Meinke</surname><given-names>PT</given-names></name><name><surname>McKernan</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Anticonvulsant and adverse effects of avermectin analogs in mice are mediated through the gamma-aminobutyric acid(A) receptor</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>295</volume><fpage>1051</fpage><lpage>1060</lpage><pub-id pub-id-type="pmid">11082440</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Gaetano</surname><given-names>G</given-names></name><name><surname>Miragliotta</surname><given-names>G</given-names></name><name><surname>Roncucci</surname><given-names>R</given-names></name><name><surname>Lansen</surname><given-names>J</given-names></name><name><surname>Lambelin</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1976">1976</year><article-title>Suloctidil: a novel inhibitor of platelet aggregation in human beings</article-title><source>Thrombosis Research</source><volume>8</volume><fpage>361</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1016/0049-3848(76)90029-3</pub-id><pub-id pub-id-type="pmid">1265708</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dierickx</surname><given-names>P</given-names></name><name><surname>Emmett</surname><given-names>MJ</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Uehara</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Adlanmerini</surname><given-names>M</given-names></name><name><surname>Lazar</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>SR9009 has REV-ERB-independent effects on cell proliferation and metabolism</article-title><source>PNAS</source><volume>116</volume><fpage>12147</fpage><lpage>12152</lpage><pub-id pub-id-type="doi">10.1073/pnas.1904226116</pub-id><pub-id pub-id-type="pmid">31127047</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doughty-Shenton</surname><given-names>D</given-names></name><name><surname>Joseph</surname><given-names>JD</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Pagliarini</surname><given-names>DJ</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Dixon</surname><given-names>JE</given-names></name><name><surname>Casey</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Pharmacological targeting of the mitochondrial phosphatase PTPMT1</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>333</volume><fpage>584</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1124/jpet.109.163329</pub-id><pub-id pub-id-type="pmid">20167843</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estrada-Mondragon</surname><given-names>A</given-names></name><name><surname>Lynch</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Functional characterization of ivermectin binding sites in α1β2γ2L GABA(A) receptors</article-title><source>Frontiers in Molecular Neuroscience</source><volume>8</volume><elocation-id>55</elocation-id><pub-id pub-id-type="doi">10.3389/fnmol.2015.00055</pub-id><pub-id pub-id-type="pmid">26441518</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>SE</given-names></name><name><surname>Lau</surname><given-names>WM</given-names></name><name><surname>Szilagyi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Blockade of a cardiac K+ channel by tacrine: interactions with muscarinic and adenosine receptors</article-title><source>European Journal of Pharmacology</source><volume>154</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(88)90363-9</pub-id><pub-id pub-id-type="pmid">3181293</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Githaka</surname><given-names>JM</given-names></name><name><surname>Dai</surname><given-names>X</given-names></name><name><surname>Plummer</surname><given-names>G</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Spigelman</surname><given-names>AF</given-names></name><name><surname>Bautista</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>R</given-names></name><name><surname>Greitzer-Antes</surname><given-names>D</given-names></name><name><surname>Fox</surname><given-names>JEM</given-names></name><name><surname>Gaisano</surname><given-names>HY</given-names></name><name><surname>MacDonald</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A glucose-dependent spatial patterning of exocytosis in human β-cells is disrupted in type 2 diabetes</article-title><source>JCI Insight</source><volume>5</volume><elocation-id>127896</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.127896</pub-id><pub-id pub-id-type="pmid">31085831</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galisteo</surname><given-names>M</given-names></name><name><surname>Rissel</surname><given-names>M</given-names></name><name><surname>Sergent</surname><given-names>O</given-names></name><name><surname>Chevanne</surname><given-names>M</given-names></name><name><surname>Cillard</surname><given-names>J</given-names></name><name><surname>Guillouzo</surname><given-names>A</given-names></name><name><surname>Lagadic-Gossmann</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Hepatotoxicity of tacrine: occurrence of membrane fluidity alterations without involvement of lipid peroxidation</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>294</volume><fpage>160</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">10871308</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gąsecka</surname><given-names>A</given-names></name><name><surname>Rogula</surname><given-names>S</given-names></name><name><surname>Eyileten</surname><given-names>C</given-names></name><name><surname>Postuła</surname><given-names>M</given-names></name><name><surname>Jaguszewski</surname><given-names>MJ</given-names></name><name><surname>Kochman</surname><given-names>J</given-names></name><name><surname>Mazurek</surname><given-names>T</given-names></name><name><surname>Nieuwland</surname><given-names>R</given-names></name><name><surname>Filipiak</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Role of P2Y Receptors in Platelet Extracellular Vesicle Release</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21176065</pub-id><pub-id pub-id-type="pmid">32842470</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaulton</surname><given-names>KJ</given-names></name><name><surname>Nammo</surname><given-names>T</given-names></name><name><surname>Pasquali</surname><given-names>L</given-names></name><name><surname>Simon</surname><given-names>JM</given-names></name><name><surname>Giresi</surname><given-names>PG</given-names></name><name><surname>Fogarty</surname><given-names>MP</given-names></name><name><surname>Panhuis</surname><given-names>TM</given-names></name><name><surname>Mieczkowski</surname><given-names>P</given-names></name><name><surname>Secchi</surname><given-names>A</given-names></name><name><surname>Bosco</surname><given-names>D</given-names></name><name><surname>Berney</surname><given-names>T</given-names></name><name><surname>Montanya</surname><given-names>E</given-names></name><name><surname>Mohlke</surname><given-names>KL</given-names></name><name><surname>Lieb</surname><given-names>JD</given-names></name><name><surname>Ferrer</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A map of open chromatin in human pancreatic islets</article-title><source>Nature Genetics</source><volume>42</volume><fpage>255</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1038/ng.530</pub-id><pub-id pub-id-type="pmid">20118932</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerst</surname><given-names>F</given-names></name><name><surname>Jaghutriz</surname><given-names>BA</given-names></name><name><surname>Staiger</surname><given-names>H</given-names></name><name><surname>Schulte</surname><given-names>AM</given-names></name><name><surname>Lorza-Gil</surname><given-names>E</given-names></name><name><surname>Kaiser</surname><given-names>G</given-names></name><name><surname>Panse</surname><given-names>M</given-names></name><name><surname>Haug</surname><given-names>S</given-names></name><name><surname>Heni</surname><given-names>M</given-names></name><name><surname>Schütz</surname><given-names>M</given-names></name><name><surname>Stadion</surname><given-names>M</given-names></name><name><surname>Schürmann</surname><given-names>A</given-names></name><name><surname>Marzetta</surname><given-names>F</given-names></name><name><surname>Ibberson</surname><given-names>M</given-names></name><name><surname>Sipos</surname><given-names>B</given-names></name><name><surname>Fend</surname><given-names>F</given-names></name><name><surname>Fleming</surname><given-names>T</given-names></name><name><surname>Nawroth</surname><given-names>PP</given-names></name><name><surname>Königsrainer</surname><given-names>A</given-names></name><name><surname>Nadalin</surname><given-names>S</given-names></name><name><surname>Wagner</surname><given-names>S</given-names></name><name><surname>Peter</surname><given-names>A</given-names></name><name><surname>Fritsche</surname><given-names>A</given-names></name><name><surname>Richter</surname><given-names>D</given-names></name><name><surname>Solimena</surname><given-names>M</given-names></name><name><surname>Häring</surname><given-names>H-U</given-names></name><name><surname>Ullrich</surname><given-names>S</given-names></name><name><surname>Wagner</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The Expression of Aldolase B in Islets Is Negatively Associated With Insulin Secretion in Humans</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>103</volume><fpage>4373</fpage><lpage>4383</lpage><pub-id pub-id-type="doi">10.1210/jc.2018-00791</pub-id><pub-id pub-id-type="pmid">30202879</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gil-Lozano</surname><given-names>M</given-names></name><name><surname>Mingomataj</surname><given-names>EL</given-names></name><name><surname>Wu</surname><given-names>WK</given-names></name><name><surname>Ridout</surname><given-names>SA</given-names></name><name><surname>Brubaker</surname><given-names>PL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Circadian secretion of the intestinal hormone GLP-1 by the rodent L cell</article-title><source>Diabetes</source><volume>63</volume><fpage>3674</fpage><lpage>3685</lpage><pub-id pub-id-type="doi">10.2337/db13-1501</pub-id><pub-id pub-id-type="pmid">24789917</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>González Canga</surname><given-names>A</given-names></name><name><surname>Sahagún Prieto</surname><given-names>AM</given-names></name><name><surname>Diez Liébana</surname><given-names>MJ</given-names></name><name><surname>Fernández Martínez</surname><given-names>N</given-names></name><name><surname>Sierra Vega</surname><given-names>M</given-names></name><name><surname>García Vieitez</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The pharmacokinetics and interactions of ivermectin in humans--a mini-review</article-title><source>The AAPS Journal</source><volume>10</volume><fpage>42</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1208/s12248-007-9000-9</pub-id><pub-id pub-id-type="pmid">18446504</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>MR</given-names></name><name><surname>Krabbe</surname><given-names>S</given-names></name><name><surname>Novak</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Purinergic receptors and calcium signalling in human pancreatic duct cell lines</article-title><source>Cellular Physiology and Biochemistry</source><volume>22</volume><fpage>157</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1159/000149793</pub-id><pub-id pub-id-type="pmid">18769042</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Hao</surname><given-names>S</given-names></name><name><surname>Andersen-Nissen</surname><given-names>E</given-names></name><name><surname>Mauck</surname><given-names>WM</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Wilk</surname><given-names>AJ</given-names></name><name><surname>Darby</surname><given-names>C</given-names></name><name><surname>Zager</surname><given-names>M</given-names></name><name><surname>Hoffman</surname><given-names>P</given-names></name><name><surname>Stoeckius</surname><given-names>M</given-names></name><name><surname>Papalexi</surname><given-names>E</given-names></name><name><surname>Mimitou</surname><given-names>EP</given-names></name><name><surname>Jain</surname><given-names>J</given-names></name><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>Stuart</surname><given-names>T</given-names></name><name><surname>Fleming</surname><given-names>LM</given-names></name><name><surname>Yeung</surname><given-names>B</given-names></name><name><surname>Rogers</surname><given-names>AJ</given-names></name><name><surname>McElrath</surname><given-names>JM</given-names></name><name><surname>Blish</surname><given-names>CA</given-names></name><name><surname>Gottardo</surname><given-names>R</given-names></name><name><surname>Smibert</surname><given-names>P</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Integrated analysis of multimodal single-cell data</article-title><source>Cell</source><volume>184</volume><fpage>3573</fpage><lpage>3587</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.04.048</pub-id><pub-id pub-id-type="pmid">34062119</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>B</given-names></name><name><surname>Nohara</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>N</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name><name><surname>Guillory</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Garcia</surname><given-names>JM</given-names></name><name><surname>Koike</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>CC</given-names></name><name><surname>Takahashi</surname><given-names>JS</given-names></name><name><surname>Yoo</surname><given-names>SH</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The Small Molecule Nobiletin Targets the Molecular Oscillator to Enhance Circadian Rhythms and Protect against Metabolic Syndrome</article-title><source>Cell Metabolism</source><volume>23</volume><fpage>610</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2016.03.007</pub-id><pub-id pub-id-type="pmid">27076076</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higashijima</surname><given-names>T</given-names></name><name><surname>Burnier</surname><given-names>J</given-names></name><name><surname>Ross</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Regulation of Gi and Go by mastoparan, related amphiphilic peptides, and hydrophobic amines</article-title><source>Mechanism and Structural Determinants of Activity. J Biol Chem</source><volume>265</volume><fpage>14176</fpage><lpage>14186</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)77284-0</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirota</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Lewis</surname><given-names>WG</given-names></name><name><surname>Zhang</surname><given-names>EE</given-names></name><name><surname>Breton</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Garcia</surname><given-names>M</given-names></name><name><surname>Peters</surname><given-names>EC</given-names></name><name><surname>Etchegaray</surname><given-names>J-P</given-names></name><name><surname>Traver</surname><given-names>D</given-names></name><name><surname>Schultz</surname><given-names>PG</given-names></name><name><surname>Kay</surname><given-names>SA</given-names></name><name><surname>Mignot</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>High-Throughput Chemical Screen Identifies a Novel Potent Modulator of Cellular Circadian Rhythms and Reveals CKIα as a Clock Regulatory Kinase</article-title><source>PLOS Biology</source><volume>8</volume><elocation-id>e1000559</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1000559</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirota</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>St John</surname><given-names>PC</given-names></name><name><surname>Sawa</surname><given-names>M</given-names></name><name><surname>Iwaisako</surname><given-names>K</given-names></name><name><surname>Noguchi</surname><given-names>T</given-names></name><name><surname>Pongsawakul</surname><given-names>PY</given-names></name><name><surname>Sonntag</surname><given-names>T</given-names></name><name><surname>Welsh</surname><given-names>DK</given-names></name><name><surname>Brenner</surname><given-names>DA</given-names></name><name><surname>Doyle</surname><given-names>FJ</given-names></name><name><surname>Schultz</surname><given-names>PG</given-names></name><name><surname>Kay</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Identification of small molecule activators of cryptochrome</article-title><source>Science</source><volume>337</volume><fpage>1094</fpage><lpage>1097</lpage><pub-id pub-id-type="doi">10.1126/science.1223710</pub-id><pub-id pub-id-type="pmid">22798407</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>ME</given-names></name><name><surname>Hogenesch</surname><given-names>JB</given-names></name><name><surname>Kornacker</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>JTK_CYCLE: an efficient nonparametric algorithm for detecting rhythmic components in genome-scale data sets</article-title><source>Journal of Biological Rhythms</source><volume>25</volume><fpage>372</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1177/0748730410379711</pub-id><pub-id pub-id-type="pmid">20876817</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Pharmacological effects of ivermectin, an antiparasitic agent for intestinal strongyloidiasis: its mode of action and clinical efficacy</article-title><source>Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica</source><volume>122</volume><fpage>527</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1254/fpj.122.527</pub-id><pub-id pub-id-type="pmid">14639007</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Isolation of Human Pancreatic Islets of Langerhans for Research V.3</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Isolation of Human Pancreatic Islets of Langerhans for Research V.3</article-title><ext-link ext-link-type="uri" xlink:href="https://www.protocols.io/view/isolation-of-human-pancreatic-islets-of-langerhans-bt55nq86">https://www.protocols.io/view/isolation-of-human-pancreatic-islets-of-langerhans-bt55nq86</ext-link><date-in-citation iso-8601-date="2021-10-22">October 22, 2021</date-in-citation></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Rong</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>Z</given-names></name><name><surname>Inaba</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism</article-title><source>Nature Communications</source><volume>4</volume><elocation-id>1937</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms2924</pub-id><pub-id pub-id-type="pmid">23728580</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlsson</surname><given-names>S</given-names></name><name><surname>Ahrén</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Effects of tacrine on insulin secretion and 86Rb+ and 45Ca++ efflux from rat pancreatic islets</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>263</volume><fpage>494</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">1331400</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khakh</surname><given-names>BS</given-names></name><name><surname>Proctor</surname><given-names>WR</given-names></name><name><surname>Dunwiddie</surname><given-names>TV</given-names></name><name><surname>Labarca</surname><given-names>C</given-names></name><name><surname>Lester</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Allosteric control of gating and kinetics at P2X(4) receptor channels</article-title><source>The Journal of Neuroscience</source><volume>19</volume><fpage>7289</fpage><lpage>7299</lpage><pub-id pub-id-type="pmid">10460235</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Yan-Do</surname><given-names>R</given-names></name><name><surname>Duong</surname><given-names>E</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Bautista</surname><given-names>A</given-names></name><name><surname>Cheley</surname><given-names>S</given-names></name><name><surname>MacDonald</surname><given-names>PE</given-names></name><name><surname>Braun</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Autocrine activation of P2Y1 receptors couples Ca (2+) influx to Ca (2+) release in human pancreatic beta cells</article-title><source>Diabetologia</source><volume>57</volume><fpage>2535</fpage><lpage>2545</lpage><pub-id pub-id-type="doi">10.1007/s00125-014-3368-8</pub-id><pub-id pub-id-type="pmid">25208758</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khanna</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Kimble-Hill</surname><given-names>A</given-names></name><name><surname>Parajuli</surname><given-names>B</given-names></name><name><surname>Perez-Miller</surname><given-names>S</given-names></name><name><surname>Baskaran</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Dria</surname><given-names>K</given-names></name><name><surname>Vasiliou</surname><given-names>V</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name><name><surname>Hurley</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Discovery of a novel class of covalent inhibitor for aldehyde dehydrogenases</article-title><source>The Journal of Biological Chemistry</source><volume>286</volume><fpage>43486</fpage><lpage>43494</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.293597</pub-id><pub-id pub-id-type="pmid">22021038</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Lazar</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transcriptional Control of Circadian Rhythms and Metabolism: A Matter of Time and Space</article-title><source>Endocrine Reviews</source><volume>41</volume><elocation-id>bnaa014</elocation-id><pub-id pub-id-type="doi">10.1210/endrev/bnaa014</pub-id><pub-id pub-id-type="pmid">32392281</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kornhuber</surname><given-names>J</given-names></name><name><surname>Tripal</surname><given-names>P</given-names></name><name><surname>Reichel</surname><given-names>M</given-names></name><name><surname>Terfloth</surname><given-names>L</given-names></name><name><surname>Bleich</surname><given-names>S</given-names></name><name><surname>Wiltfang</surname><given-names>J</given-names></name><name><surname>Gulbins</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model</article-title><source>Journal of Medicinal Chemistry</source><volume>51</volume><fpage>219</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1021/jm070524a</pub-id><pub-id pub-id-type="pmid">18027916</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamia</surname><given-names>KA</given-names></name><name><surname>Storch</surname><given-names>KF</given-names></name><name><surname>Weitz</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Physiological significance of a peripheral tissue circadian clock</article-title><source>PNAS</source><volume>105</volume><fpage>15172</fpage><lpage>15177</lpage><pub-id pub-id-type="doi">10.1073/pnas.0806717105</pub-id><pub-id pub-id-type="pmid">18779586</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>C</given-names></name><name><surname>Staiger</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tyrothricin--An underrated agent for the treatment of bacterial skin infections and superficial wounds?</article-title><source>Die Pharmazie</source><volume>71</volume><fpage>299</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">27455547</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Léon</surname><given-names>C</given-names></name><name><surname>Freund</surname><given-names>M</given-names></name><name><surname>Latchoumanin</surname><given-names>O</given-names></name><name><surname>Farret</surname><given-names>A</given-names></name><name><surname>Petit</surname><given-names>P</given-names></name><name><surname>Cazenave</surname><given-names>J-P</given-names></name><name><surname>Gachet</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The P2Y(1) receptor is involved in the maintenance of glucose homeostasis and in insulin secretion in mice</article-title><source>Purinergic Signalling</source><volume>1</volume><fpage>145</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1007/s11302-005-6209-x</pub-id><pub-id pub-id-type="pmid">18404499</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>DC</given-names></name><name><surname>Hong</surname><given-names>H</given-names></name><name><surname>Weidemann</surname><given-names>BJ</given-names></name><name><surname>Ramsey</surname><given-names>KM</given-names></name><name><surname>Affinati</surname><given-names>AH</given-names></name><name><surname>Schmidt</surname><given-names>MS</given-names></name><name><surname>Cedernaes</surname><given-names>J</given-names></name><name><surname>Omura</surname><given-names>C</given-names></name><name><surname>Braun</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Brenner</surname><given-names>C</given-names></name><name><surname>Peek</surname><given-names>CB</given-names></name><name><surname>Bass</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>NAD+ Controls Circadian Reprogramming through PER2 Nuclear Translocation to Counter Aging</article-title><source>Molecular Cell</source><volume>78</volume><fpage>835</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.04.010</pub-id><pub-id pub-id-type="pmid">32369735</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linn</surname><given-names>DK</given-names></name><name><surname>Zimmerman</surname><given-names>TJ</given-names></name><name><surname>Nardin</surname><given-names>GF</given-names></name><name><surname>Yung</surname><given-names>R</given-names></name><name><surname>Berberich</surname><given-names>S</given-names></name><name><surname>DuBiner</surname><given-names>H</given-names></name><name><surname>Fuqua</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Effect of intracameral carbachol on intraocular pressure after cataract extraction</article-title><source>American Journal of Ophthalmology</source><volume>107</volume><fpage>133</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/0002-9394(89)90211-0</pub-id><pub-id pub-id-type="pmid">2913806</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lommen</surname><given-names>J</given-names></name><name><surname>Stahr</surname><given-names>A</given-names></name><name><surname>Ingenwerth</surname><given-names>M</given-names></name><name><surname>Ali</surname><given-names>AAH</given-names></name><name><surname>von Gall</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Time-of-day-dependent expression of purinergic receptors in mouse suprachiasmatic nucleus</article-title><source>Cell and Tissue Research</source><volume>369</volume><fpage>579</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1007/s00441-017-2634-8</pub-id><pub-id pub-id-type="pmid">28547658</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>NZ</given-names></name><name><surname>Wardell</surname><given-names>SE</given-names></name><name><surname>Burnstein</surname><given-names>KL</given-names></name><name><surname>Defranco</surname><given-names>D</given-names></name><name><surname>Fuller</surname><given-names>PJ</given-names></name><name><surname>Giguere</surname><given-names>V</given-names></name><name><surname>Hochberg</surname><given-names>RB</given-names></name><name><surname>McKay</surname><given-names>L</given-names></name><name><surname>Renoir</surname><given-names>J-M</given-names></name><name><surname>Weigel</surname><given-names>NL</given-names></name><name><surname>Wilson</surname><given-names>EM</given-names></name><name><surname>McDonnell</surname><given-names>DP</given-names></name><name><surname>Cidlowski</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors</article-title><source>Pharmacological Reviews</source><volume>58</volume><fpage>782</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1124/pr.58.4.9</pub-id><pub-id pub-id-type="pmid">17132855</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcheva</surname><given-names>B</given-names></name><name><surname>Ramsey</surname><given-names>KM</given-names></name><name><surname>Buhr</surname><given-names>ED</given-names></name><name><surname>Kobayashi</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>H</given-names></name><name><surname>Ko</surname><given-names>CH</given-names></name><name><surname>Ivanova</surname><given-names>G</given-names></name><name><surname>Omura</surname><given-names>C</given-names></name><name><surname>Mo</surname><given-names>S</given-names></name><name><surname>Vitaterna</surname><given-names>MH</given-names></name><name><surname>Lopez</surname><given-names>JP</given-names></name><name><surname>Philipson</surname><given-names>LH</given-names></name><name><surname>Bradfield</surname><given-names>CA</given-names></name><name><surname>Crosby</surname><given-names>SD</given-names></name><name><surname>JeBailey</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Takahashi</surname><given-names>JS</given-names></name><name><surname>Bass</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes</article-title><source>Nature</source><volume>466</volume><fpage>627</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1038/nature09253</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcheva</surname><given-names>B</given-names></name><name><surname>Perelis</surname><given-names>M</given-names></name><name><surname>Weidemann</surname><given-names>BJ</given-names></name><name><surname>Taguchi</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Omura</surname><given-names>C</given-names></name><name><surname>Kobayashi</surname><given-names>Y</given-names></name><name><surname>Newman</surname><given-names>MV</given-names></name><name><surname>Wyatt</surname><given-names>EJ</given-names></name><name><surname>McNally</surname><given-names>EM</given-names></name><name><surname>Fox</surname><given-names>JEM</given-names></name><name><surname>Hong</surname><given-names>H</given-names></name><name><surname>Shankar</surname><given-names>A</given-names></name><name><surname>Wheeler</surname><given-names>EC</given-names></name><name><surname>Ramsey</surname><given-names>KM</given-names></name><name><surname>MacDonald</surname><given-names>PE</given-names></name><name><surname>Yeo</surname><given-names>GW</given-names></name><name><surname>Bass</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A role for alternative splicing in circadian control of exocytosis and glucose homeostasis</article-title><source>Genes &amp; Development</source><volume>34</volume><fpage>1089</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.1101/gad.338178.120</pub-id><pub-id pub-id-type="pmid">32616519</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marco</surname><given-names>JL</given-names></name><name><surname>Carreiras</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Recent developments in the synthesis of acetylcholinesterase inhibitors</article-title><source>Mini Reviews in Medicinal Chemistry</source><volume>3</volume><fpage>518</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.2174/1389557033487908</pub-id><pub-id pub-id-type="pmid">12871155</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milner</surname><given-names>SE</given-names></name><name><surname>Brunton</surname><given-names>NP</given-names></name><name><surname>Jones</surname><given-names>PW</given-names></name><name><surname>O’Brien</surname><given-names>NM</given-names></name><name><surname>Collins</surname><given-names>SG</given-names></name><name><surname>Maguire</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Bioactivities of glycoalkaloids and their aglycones from Solanum species</article-title><source>Journal of Agricultural and Food Chemistry</source><volume>59</volume><fpage>3454</fpage><lpage>3484</lpage><pub-id pub-id-type="doi">10.1021/jf200439q</pub-id><pub-id pub-id-type="pmid">21401040</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moffat</surname><given-names>JG</given-names></name><name><surname>Vincent</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>JA</given-names></name><name><surname>Eder</surname><given-names>J</given-names></name><name><surname>Prunotto</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Opportunities and challenges in phenotypic drug discovery: an industry perspective</article-title><source>Nature Reviews. Drug Discovery</source><volume>16</volume><fpage>531</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.111</pub-id><pub-id pub-id-type="pmid">28685762</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>TH</given-names></name><name><surname>Worley</surname><given-names>PF</given-names></name><name><surname>Nakabeppu</surname><given-names>Y</given-names></name><name><surname>Christy</surname><given-names>B</given-names></name><name><surname>Gastel</surname><given-names>J</given-names></name><name><surname>Baraban</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Synaptic regulation of immediate early gene expression in primary cultures of cortical neurons</article-title><source>Journal of Neurochemistry</source><volume>57</volume><fpage>1862</fpage><lpage>1872</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.1991.tb06396.x</pub-id><pub-id pub-id-type="pmid">1719131</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagata</surname><given-names>M</given-names></name><name><surname>Yokooji</surname><given-names>T</given-names></name><name><surname>Nakai</surname><given-names>T</given-names></name><name><surname>Miura</surname><given-names>Y</given-names></name><name><surname>Tomita</surname><given-names>T</given-names></name><name><surname>Taogoshi</surname><given-names>T</given-names></name><name><surname>Sugimoto</surname><given-names>Y</given-names></name><name><surname>Matsuo</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Blockade of multiple monoamines receptors reduce insulin secretion from pancreatic β-cells</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>16438</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-52590-y</pub-id><pub-id pub-id-type="pmid">31712714</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nath</surname><given-names>AK</given-names></name><name><surname>Ryu</surname><given-names>JH</given-names></name><name><surname>Jin</surname><given-names>YN</given-names></name><name><surname>Roberts</surname><given-names>LD</given-names></name><name><surname>Dejam</surname><given-names>A</given-names></name><name><surname>Gerszten</surname><given-names>RE</given-names></name><name><surname>Peterson</surname><given-names>RT</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>PTPMT1 Inhibition Lowers Glucose through Succinate Dehydrogenase Phosphorylation</article-title><source>Cell Reports</source><volume>10</volume><fpage>694</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.01.010</pub-id><pub-id pub-id-type="pmid">25660020</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohtani</surname><given-names>M</given-names></name><name><surname>Ohura</surname><given-names>K</given-names></name><name><surname>Oka</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Involvement of P2X receptors in the regulation of insulin secretion, proliferation and survival in mouse pancreatic β-cells</article-title><source>Cellular Physiology and Biochemistry</source><volume>28</volume><fpage>355</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1159/000331752</pub-id><pub-id pub-id-type="pmid">21865744</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peek</surname><given-names>CB</given-names></name><name><surname>Affinati</surname><given-names>AH</given-names></name><name><surname>Ramsey</surname><given-names>KM</given-names></name><name><surname>Kuo</surname><given-names>HY</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Sena</surname><given-names>LA</given-names></name><name><surname>Ilkayeva</surname><given-names>O</given-names></name><name><surname>Marcheva</surname><given-names>B</given-names></name><name><surname>Kobayashi</surname><given-names>Y</given-names></name><name><surname>Omura</surname><given-names>C</given-names></name><name><surname>Levine</surname><given-names>DC</given-names></name><name><surname>Bacsik</surname><given-names>DJ</given-names></name><name><surname>Gius</surname><given-names>D</given-names></name><name><surname>Newgard</surname><given-names>CB</given-names></name><name><surname>Goetzman</surname><given-names>E</given-names></name><name><surname>Chandel</surname><given-names>NS</given-names></name><name><surname>Denu</surname><given-names>JM</given-names></name><name><surname>Mrksich</surname><given-names>M</given-names></name><name><surname>Bass</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Circadian clock NAD+ cycle drives mitochondrial oxidative metabolism in mice</article-title><source>Science</source><volume>342</volume><elocation-id>1243417</elocation-id><pub-id pub-id-type="doi">10.1126/science.1243417</pub-id><pub-id pub-id-type="pmid">24051248</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perelis</surname><given-names>M</given-names></name><name><surname>Marcheva</surname><given-names>B</given-names></name><name><surname>Ramsey</surname><given-names>KM</given-names></name><name><surname>Schipma</surname><given-names>MJ</given-names></name><name><surname>Hutchison</surname><given-names>AL</given-names></name><name><surname>Taguchi</surname><given-names>A</given-names></name><name><surname>Peek</surname><given-names>CB</given-names></name><name><surname>Hong</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Omura</surname><given-names>C</given-names></name><name><surname>Allred</surname><given-names>AL</given-names></name><name><surname>Bradfield</surname><given-names>CA</given-names></name><name><surname>Dinner</surname><given-names>AR</given-names></name><name><surname>Barish</surname><given-names>GD</given-names></name><name><surname>Bass</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Pancreatic β cell enhancers regulate rhythmic transcription of genes controlling insulin secretion</article-title><source>Science</source><volume>350</volume><elocation-id>aac4250</elocation-id><pub-id pub-id-type="doi">10.1126/science.aac4250</pub-id><pub-id pub-id-type="pmid">26542580</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perelis</surname><given-names>M</given-names></name><name><surname>Ramsey</surname><given-names>KM</given-names></name><name><surname>Marcheva</surname><given-names>B</given-names></name><name><surname>Bass</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Circadian Transcription from Beta Cell Function to Diabetes Pathophysiology</article-title><source>Journal of Biological Rhythms</source><volume>31</volume><fpage>323</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1177/0748730416656949</pub-id><pub-id pub-id-type="pmid">27440914</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrenko</surname><given-names>V</given-names></name><name><surname>Gandasi</surname><given-names>NR</given-names></name><name><surname>Sage</surname><given-names>D</given-names></name><name><surname>Tengholm</surname><given-names>A</given-names></name><name><surname>Barg</surname><given-names>S</given-names></name><name><surname>Dibner</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>In pancreatic islets from type 2 diabetes patients, the dampened circadian oscillators lead to reduced insulin and glucagon exocytosis</article-title><source>PNAS</source><volume>117</volume><fpage>2484</fpage><lpage>2495</lpage><pub-id pub-id-type="doi">10.1073/pnas.1916539117</pub-id><pub-id pub-id-type="pmid">31964806</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrenko</surname><given-names>V</given-names></name><name><surname>Stolovich-Rain</surname><given-names>M</given-names></name><name><surname>Vandereycken</surname><given-names>B</given-names></name><name><surname>Giovannoni</surname><given-names>L</given-names></name><name><surname>Storch</surname><given-names>KF</given-names></name><name><surname>Dor</surname><given-names>Y</given-names></name><name><surname>Chera</surname><given-names>S</given-names></name><name><surname>Dibner</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>The core clock transcription factor BMAL1 drives circadian β-cell proliferation during compensatory regeneration of the endocrine pancreas</article-title><source>Genes &amp; Development</source><volume>34</volume><fpage>1650</fpage><lpage>1665</lpage><pub-id pub-id-type="doi">10.1101/gad.343137.120</pub-id><pub-id pub-id-type="pmid">33184223</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prentice</surname><given-names>KJ</given-names></name><name><surname>Saksi</surname><given-names>J</given-names></name><name><surname>Robertson</surname><given-names>LT</given-names></name><name><surname>Lee</surname><given-names>GY</given-names></name><name><surname>Inouye</surname><given-names>KE</given-names></name><name><surname>Eguchi</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Cakici</surname><given-names>O</given-names></name><name><surname>Otterbeck</surname><given-names>E</given-names></name><name><surname>Cedillo</surname><given-names>P</given-names></name><name><surname>Achenbach</surname><given-names>P</given-names></name><name><surname>Ziegler</surname><given-names>AG</given-names></name><name><surname>Calay</surname><given-names>ES</given-names></name><name><surname>Engin</surname><given-names>F</given-names></name><name><surname>Hotamisligil</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A hormone complex of FABP4 and nucleoside kinases regulates islet function</article-title><source>Nature</source><volume>600</volume><fpage>720</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04137-3</pub-id><pub-id pub-id-type="pmid">34880500</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priel</surname><given-names>A</given-names></name><name><surname>Silberberg</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Mechanism of ivermectin facilitation of human P2X4 receptor channels</article-title><source>The Journal of General Physiology</source><volume>123</volume><fpage>281</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1085/jgp.200308986</pub-id><pub-id pub-id-type="pmid">14769846</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ratajewski</surname><given-names>M</given-names></name><name><surname>Grzelak</surname><given-names>I</given-names></name><name><surname>Wiśniewska</surname><given-names>K</given-names></name><name><surname>Ryba</surname><given-names>K</given-names></name><name><surname>Gorzkiewicz</surname><given-names>M</given-names></name><name><surname>Walczak-Drzewiecka</surname><given-names>A</given-names></name><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Dastych</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Screening of a chemical library reveals novel PXR-activating pharmacologic compounds</article-title><source>Toxicology Letters</source><volume>232</volume><fpage>193</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2014.10.009</pub-id><pub-id pub-id-type="pmid">25455453</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinne</surname><given-names>A</given-names></name><name><surname>Mobarec</surname><given-names>JC</given-names></name><name><surname>Mahaut-Smith</surname><given-names>M</given-names></name><name><surname>Kolb</surname><given-names>P</given-names></name><name><surname>Bünemann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The mode of agonist binding to a G protein-coupled receptor switches the effect that voltage changes have on signaling</article-title><source>Science Signaling</source><volume>8</volume><elocation-id>401</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aac7419</pub-id><pub-id pub-id-type="pmid">26535008</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roghani</surname><given-names>S</given-names></name><name><surname>Duperon</surname><given-names>DF</given-names></name><name><surname>Barcohana</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Evaluating the efficacy of commonly used topical anesthetics</article-title><source>Pediatric Dentistry</source><volume>21</volume><fpage>197</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">10355012</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rorsman</surname><given-names>P</given-names></name><name><surname>Renström</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Insulin granule dynamics in pancreatic beta cells</article-title><source>Diabetologia</source><volume>46</volume><fpage>1029</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1007/s00125-003-1153-1</pub-id><pub-id pub-id-type="pmid">12879249</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberry</surname><given-names>TL</given-names></name><name><surname>Sonoda</surname><given-names>LK</given-names></name><name><surname>Dekat</surname><given-names>SE</given-names></name><name><surname>Cusack</surname><given-names>B</given-names></name><name><surname>Johnson</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Analysis of the reaction of carbachol with acetylcholinesterase using thioflavin T as a coupled fluorescence reporter</article-title><source>Biochemistry</source><volume>47</volume><fpage>13056</fpage><lpage>13063</lpage><pub-id pub-id-type="doi">10.1021/bi8015197</pub-id><pub-id pub-id-type="pmid">19006330</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadacca</surname><given-names>LA</given-names></name><name><surname>Lamia</surname><given-names>KA</given-names></name><name><surname>Blum</surname><given-names>B</given-names></name><name><surname>Weitz</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>An intrinsic circadian clock of the pancreas is required for normal insulin release and glucose homeostasis in mice</article-title><source>Diabetologia</source><volume>54</volume><fpage>120</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1007/s00125-010-1920-8</pub-id><pub-id pub-id-type="pmid">20890745</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahdeo</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>BD</given-names></name><name><surname>McMackin</surname><given-names>MZ</given-names></name><name><surname>Jasoliya</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>B</given-names></name><name><surname>Wulff</surname><given-names>H</given-names></name><name><surname>Perlman</surname><given-names>SL</given-names></name><name><surname>Pook</surname><given-names>MA</given-names></name><name><surname>Cortopassi</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich’s ataxia</article-title><source>Human Molecular Genetics</source><volume>23</volume><fpage>6848</fpage><lpage>6862</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddu408</pub-id><pub-id pub-id-type="pmid">25113747</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Solanas</surname><given-names>G</given-names></name><name><surname>Peixoto</surname><given-names>FO</given-names></name><name><surname>Bee</surname><given-names>L</given-names></name><name><surname>Symeonidi</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>MS</given-names></name><name><surname>Brenner</surname><given-names>C</given-names></name><name><surname>Masri</surname><given-names>S</given-names></name><name><surname>Benitah</surname><given-names>SA</given-names></name><name><surname>Sassone-Corsi</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Circadian Reprogramming in the Liver Identifies Metabolic Pathways of Aging</article-title><source>Cell</source><volume>170</volume><fpage>664</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.07.042</pub-id><pub-id pub-id-type="pmid">28802039</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segerstolpe</surname><given-names>Å</given-names></name><name><surname>Palasantza</surname><given-names>A</given-names></name><name><surname>Eliasson</surname><given-names>P</given-names></name><name><surname>Andersson</surname><given-names>E-M</given-names></name><name><surname>Andréasson</surname><given-names>A-C</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Picelli</surname><given-names>S</given-names></name><name><surname>Sabirsh</surname><given-names>A</given-names></name><name><surname>Clausen</surname><given-names>M</given-names></name><name><surname>Bjursell</surname><given-names>MK</given-names></name><name><surname>Smith</surname><given-names>DM</given-names></name><name><surname>Kasper</surname><given-names>M</given-names></name><name><surname>Ämmälä</surname><given-names>C</given-names></name><name><surname>Sandberg</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes</article-title><source>Cell Metabolism</source><volume>24</volume><fpage>593</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2016.08.020</pub-id><pub-id pub-id-type="pmid">27667667</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shih</surname><given-names>YW</given-names></name><name><surname>Shieh</surname><given-names>JM</given-names></name><name><surname>Wu</surname><given-names>PF</given-names></name><name><surname>Lee</surname><given-names>YC</given-names></name><name><surname>Chen</surname><given-names>YZ</given-names></name><name><surname>Chiang</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Alpha-tomatine inactivates PI3K/Akt and ERK signaling pathways in human lung adenocarcinoma A549 cells: effect on metastasis</article-title><source>Food and Chemical Toxicology</source><volume>47</volume><fpage>1985</fpage><lpage>1995</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2009.05.011</pub-id><pub-id pub-id-type="pmid">19457446</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soltani</surname><given-names>N</given-names></name><name><surname>Qiu</surname><given-names>H</given-names></name><name><surname>Aleksic</surname><given-names>M</given-names></name><name><surname>Glinka</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Chakrabarti</surname><given-names>R</given-names></name><name><surname>Ng</surname><given-names>T</given-names></name><name><surname>Jin</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>WY</given-names></name><name><surname>Feng</surname><given-names>ZP</given-names></name><name><surname>Prud’homme</surname><given-names>GJ</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes</article-title><source>PNAS</source><volume>108</volume><fpage>11692</fpage><lpage>11697</lpage><pub-id pub-id-type="doi">10.1073/pnas.1102715108</pub-id><pub-id pub-id-type="pmid">21709230</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutton</surname><given-names>EF</given-names></name><name><surname>Beyl</surname><given-names>R</given-names></name><name><surname>Early</surname><given-names>KS</given-names></name><name><surname>Cefalu</surname><given-names>WT</given-names></name><name><surname>Ravussin</surname><given-names>E</given-names></name><name><surname>Peterson</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Early Time-Restricted Feeding Improves Insulin Sensitivity, Blood Pressure, and Oxidative Stress Even without Weight Loss in Men with Prediabetes</article-title><source>Cell Metabolism</source><volume>27</volume><fpage>1212</fpage><lpage>1221</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.04.010</pub-id><pub-id pub-id-type="pmid">29754952</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svobodova</surname><given-names>I</given-names></name><name><surname>Bhattaracharya</surname><given-names>A</given-names></name><name><surname>Ivetic</surname><given-names>M</given-names></name><name><surname>Bendova</surname><given-names>Z</given-names></name><name><surname>Zemkova</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Circadian ATP Release in Organotypic Cultures of the Rat Suprachiasmatic Nucleus Is Dependent on P2X7 and P2Y Receptors</article-title><source>Frontiers in Pharmacology</source><volume>9</volume><elocation-id>192</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2018.00192</pub-id><pub-id pub-id-type="pmid">29559915</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Craenenbroeck</surname><given-names>K</given-names></name><name><surname>Gellynck</surname><given-names>E</given-names></name><name><surname>Lintermans</surname><given-names>B</given-names></name><name><surname>Leysen</surname><given-names>JE</given-names></name><name><surname>Van Tol</surname><given-names>HHM</given-names></name><name><surname>Haegeman</surname><given-names>G</given-names></name><name><surname>Vanhoenacker</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Influence of the antipsychotic drug pipamperone on the expression of the dopamine D4 receptor</article-title><source>Life Sciences</source><volume>80</volume><fpage>74</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2006.08.024</pub-id><pub-id pub-id-type="pmid">16978659</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vitaterna</surname><given-names>MH</given-names></name><name><surname>Selby</surname><given-names>CP</given-names></name><name><surname>Todo</surname><given-names>T</given-names></name><name><surname>Niwa</surname><given-names>H</given-names></name><name><surname>Thompson</surname><given-names>C</given-names></name><name><surname>Fruechte</surname><given-names>EM</given-names></name><name><surname>Hitomi</surname><given-names>K</given-names></name><name><surname>Thresher</surname><given-names>RJ</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Miyazaki</surname><given-names>J</given-names></name><name><surname>Takahashi</surname><given-names>JS</given-names></name><name><surname>Sancar</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Differential regulation of mammalian period genes and circadian rhythmicity by cryptochromes 1 and 2</article-title><source>PNAS</source><volume>96</volume><fpage>12114</fpage><lpage>12119</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.21.12114</pub-id><pub-id pub-id-type="pmid">10518585</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>JY</given-names></name><name><surname>Hsu</surname><given-names>TT</given-names></name><name><surname>Sun</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Functional characterization of P2Y1 versus P2X receptors in RBA-2 astrocytes: elucidate the roles of ATP release and protein kinase C</article-title><source>Journal of Cellular Biochemistry</source><volume>104</volume><fpage>554</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1002/jcb.21645</pub-id><pub-id pub-id-type="pmid">18072286</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woehrle</surname><given-names>T</given-names></name><name><surname>Ledderose</surname><given-names>C</given-names></name><name><surname>Rink</surname><given-names>J</given-names></name><name><surname>Slubowski</surname><given-names>C</given-names></name><name><surname>Junger</surname><given-names>WG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Autocrine stimulation of P2Y1 receptors is part of the purinergic signaling mechanism that regulates T cell activation</article-title><source>Purinergic Signalling</source><volume>15</volume><fpage>127</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1007/s11302-019-09653-6</pub-id><pub-id pub-id-type="pmid">30919205</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshioka</surname><given-names>M</given-names></name><name><surname>Kayo</surname><given-names>T</given-names></name><name><surname>Ikeda</surname><given-names>T</given-names></name><name><surname>Koizumi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice</article-title><source>Diabetes</source><volume>46</volume><fpage>887</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.2337/diab.46.5.887</pub-id><pub-id pub-id-type="pmid">9133560</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>JH</given-names></name><name><surname>Chung</surname><given-names>TD</given-names></name><name><surname>Oldenburg</surname><given-names>KR</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays</article-title><source>Journal of Biomolecular Screening</source><volume>4</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1177/108705719900400206</pub-id><pub-id pub-id-type="pmid">10838414</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Lahens</surname><given-names>NF</given-names></name><name><surname>Ballance</surname><given-names>HI</given-names></name><name><surname>Hughes</surname><given-names>ME</given-names></name><name><surname>Hogenesch</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A circadian gene expression atlas in mammals: implications for biology and medicine</article-title><source>PNAS</source><volume>111</volume><fpage>16219</fpage><lpage>16224</lpage><pub-id pub-id-type="doi">10.1073/pnas.1408886111</pub-id><pub-id pub-id-type="pmid">25349387</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.75132.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kramer</surname><given-names>Achim</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/001w7jn25</institution-id><institution>Charite Universitaetsmedizin Berlin</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2021.11.05.467499" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2021.11.05.467499"/></front-stub><body><p>Circadian disruption is widespread in our modern 24/7 society, leading to an increased prevalence of common diseases including type 2 diabetes. The authors conducted an unbiased screen for small-molecule compounds that can restore the attenuated insulin secretion from pancreatic β-cells caused by a disrupted circadian clock. They identified ivermectin and its clock-controlled target, the P2Y1 receptor, which regulate glucose-stimulated ca<sup>2+</sup> influx and insulin secretion in β-cells. This discovery represents an important advance in our understanding of regulatory mechanisms of insulin secretion by cell-autonomous clocks in mouse and human β-cells and is of fundamental clinical importance in context of novel therapeutic targets for diabetes management.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.75132.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kramer</surname><given-names>Achim</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/001w7jn25</institution-id><institution>Charite Universitaetsmedizin Berlin</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Dibner</surname><given-names>Charna</given-names></name><role>Reviewer</role><aff><institution>University of Geneva</institution><country>Switzerland</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.11.05.467499">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.11.05.467499v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Pharmacologic rescue of circadian β-cell failure through P2Y1 purinergic receptor identified by small-molecule screen&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Didier Stainier as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Charna Dibner (Reviewer #1).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Analyze the specificity of ivermectin for modulating insulin secretion regarding Bmal1-KO and β-cells, respectively. Test ivermectin on other endocrine cell types and other models for clock disruption.</p><p>2) Perform control experiments as requested by reviewer #2, major point 4, in particular those for experiments described in Figure 3 and Figure 4.</p><p>3) Discuss novelty compared to Burns et al., 2015.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Type 2 diabetes (T2D) is a prevalent metabolic disease that is phenotypically characterized by the loss of ß cell secretory function and cell mass. Its pathophysiology is complex and includes a combination of genetic and environmental risk factors. Studies in humans suggest that circadian misalignment (e.g. under shift work schedules) and disrupted sleep are associated with an increased incidence of T2D, as well as signs of ß cell failure and insulin insensitivity. In addition, mouse studies have confirmed that deletions of key components of the molecular clock disrupt normal glucose homeostasis, ß cell function, and insulin secretion. Global Bmal1 KO and pancreatic Bmal1 KO have been shown to negatively impact glucose tolerance, glucose stimulated insulin secretion, and pancreatic islet size. However, despite a relatively clear connection between circadian disruption and risk for development of T2D, molecular mechanisms are yet to be described in detail and hold potential for contributing to the development of novel therapeutic and preventative strategies.</p><p>The authors aim to tackle these questions by identifying pharmacological compounds that improve the phenotype of circadian ß cell failure, as well as by further describing the mode of action of their final target compound.</p><p>1) Do the authors believe that the pharmacological compound hit they identify in their screen is specific for Bmal1 KO induced ß cell failure or is the disruption of circadian rhythmicity more important than knock-out of this specific gene? Since they have the insulin-nanoluciferase reporter and the compound library they could perform a smaller sub-screen with selected candidates in a model of circadian ß cell failure that is different from Bmal1 KO.</p><p>2) My impression was that the authors are interested in finding pharmacological compounds that can rescue circadian ß cell failure. However, many of their results show that ivermectin also enhances insulin secretion in wild type cells/islets. So what is the conclusion of the authors? Did they just find &quot;another drug for treatment of ß cell failure&quot; or is it really specific for ß cell failure originating from circadian disruption (or perhaps Bmal1 KO)? If the former is the case, what would be the benefit of performing a compound screen in Bmal1 KO ß cells rather then in other established models of ß cell failure or wild type ß cells?</p><p>Specifically, I am referring to Figures Figure 3: Here the authors show that ivermectin treatment enhances glucose dependent insulin secretion, calcium influx, and membrane capacitance also in wild type islets. Why did they not test the effect of ivermectin on calcium influx and on insulin secretion in the perifusion system using their Bmal1 mutant islets?</p><p>Generally the effect of ivermectin in wild type cells/islets appears somewhat inconsistent. For example, it does not enhance membrane capacitance in wild type mouse islets but it does enhance it in human islets. In Figure 3D glucose + ivermectin treatment completely rescues insulin release in Bmal1 mutant islets (release is similar to wild type levels) but in Figure 4D it does not. Can the authors discuss this?</p><p>3) In their study from 2015, Burns et al., (Cell Metabolism, reference 76.) developed a insulin-gaussia luciferase reporter that to my understanding is identical to the insulin-nanoluciferase reporter except for exchange of the luciferase enzyme. Burns et al., also used their reporter system to screen for modifiers of insulin secretion in a high-throughput format. Could the authors please elaborate why they chose to replace gaussia by nanoluciferase and what is novel/beneficial about their approach?</p><p>4) Some important experimental controls are missing in some of the experiments (as follows). Also it is unclear why for some experiments the authors used 2mM &quot;basal glucose&quot; as control condition and sometimes they used 0mM glucose. Could they please explain?</p><p>Figure 3B – why are Bmal1 KO islets not included?</p><p>Figure 3C – again, why no Bmal1 KO islets?</p><p>Figure 4B – why is there no control with no glucose and just MRS?</p><p>Figure 4C – again, why is there no control with just MRS?</p><p>Figure S2D – 0mM glucose + Isr is missing</p><p>Figure S2E – again control with just Isr is missing</p><p>Figure S3B – P2ry1 transcript is rhythmic in wild type ß cells but is it's rhythmicity really lost in Bmal1 KO ß cells? (if the authors claim that P2ry1 is regulated by BMAL1 they should check this)</p><p>5) Could the authors elaborate on their strategy to identify potential ivermectin targets? It appears that ivermectin also augments insulin secretion in wild type cells, so is it really logical to check for transcripts that are already highly expressed in wild type? Wouldn't it be more intuitive to look for the top differentially expressed genes in wild type vs. Bmal1 KO ß cells? Also I would like to point out that the display of the differential gene expression data (Figure S3A) is difficult to understand for the reader. Rather than plotting the p-value the authors could show the log-fold change of expression (or similar) so that the reader can comprehend Bmal1 KO induced changes.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.75132.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Analyze the specificity of ivermectin for modulating insulin secretion regarding Bmal1-KO and β-cells, respectively. Test ivermectin on other endocrine cell types and other models for clock disruption.</p></disp-quote><p>We thank the Reviewers for these helpful suggestions. In our revised manuscript, we include new data from clock-disrupted cryptochrome (<italic>Cry1<sup>-/-</sup>; Cry2<sup>-/-</sup></italic>) knockout mice. We show that islets isolated from these mice display impaired glucose-stimulated insulin secretion yet remain responsive to ivermectin (IVM) (new Figure 3D), similar to our findings in pancreas-specific <italic>Bmal1<sup>-/-</sup></italic> mice (Figure 3B). Inclusion of this new data suggests that the restoration of insulin secretion in <italic>Bmal1<sup>-/-</sup></italic> cells by IVM is due to rescue of a defect caused by the circadian clock network as opposed to a non-circadian effect of deletion of a specific transcription factor.</p><p>p7. We have added the following text: <italic>“</italic>Additionally, we observed a similar 2.9-fold increase in GSIS following administration of IVM to islets isolated from an independent mouse model of circadian disruption (Cry1<sup>-/-</sup>; Cry2<sup>-/-</sup> mice) (Figure 3D), suggesting that IVM ameliorates secretory defects caused by disruption of the circadian clock network.<italic>”</italic></p><p>We also appreciate the suggestion to assess the possible effect of IVM on other endocrine cell types within the islets. Since our screen was performed in an exclusively β-cell culture, it is unlikely that IVM effects on other endocrine cell types, particularly glucagon-secreting α cells, explain the insulinotropic effects of IVM in whole islets studies. While we cannot rule out effects of IVM on other cell types, we now provide data from our new single-cell RNA-sequencing analysis (SRA accession ERP017126) in human islets that shows that <italic>P2RY1</italic> expression is enriched in insulin-producing β cells but not within glucagon-expressing α cells (new Figure 4—figure supplement 1C) (1). Therefore, we do not believe that IVM action through P2Y1 within α cells contributes to the enhanced insulin secretion observed in these islets.</p><p>p8. We have added the following text<italic>:</italic> “Finally, analysis of RNA-sequencing data from human islets (SRA accession ERP017126) indicates that P2RY1 expression is enriched within β cells among hormone-secreting cell types, with little to no detectable expression in the glucagon-secreting α cells (Figure 4—figure supplement 1C).”</p><disp-quote content-type="editor-comment"><p>2) Perform control experiments as requested by reviewer #2, major point 4, in particular those for experiments described in Figure 3 and Figure 4.</p></disp-quote><p>In our revised manuscript, we now include the controls requested by Reviewer 2 in Major Comment 4.</p><p>(i) A prior critique was the lack of a dynamic assessment of insulin secretion in IVM-treated <italic>Bmal1<sup>-/-</sup></italic> islets. In response, we have now performed dynamic perifusion experiments, where we measure insulin every 2 min over the course of 30 min following stimulation with either 20 mM glucose or 20 mM glucose plus 10 µM IVM. While <italic>Bmal1<sup>-/-</sup></italic> islets exhibit reduced glucose-stimulated insulin release, IVM enhances <italic>Bmal1<sup>-/-</sup></italic> islet insulin secretion to the same level observed in islets from control mice not exposed to drug during both the initial burst of insulin secretion (first 12 min) and the sustained release (12 – 30 min). These results provide new dynamic evidence for IVM-augmentation of glucose-stimulated insulin secretion in the setting of molecular clock disruption (new Figure 3C).</p><p>p7. We have added the following text: “Furthermore, perifusion experiments in islets from Bmal1 mutant mice revealed that IVM significantly increased insulin release during both the initial burst of secretion (first 12 minutes post-stimulation) and during the sustained release (12-30 min) in both WT and Bmal1 mutant islets (Figure 3C).”</p><p>(ii) We present new control data demonstrating that the P2Y1 inhibitor MRS2179 (MRS) has no effect on insulin secretion or calcium influx in the absence of glucose (new Figure 4B-C).</p><p>(iii) We also show new control data demonstrating that the calcium channel inhibitor isradipine (Isr) decreases insulin secretion and calcium influx regardless of the presence of glucose or IVM, suggesting IVM acts upstream of calcium channel signaling (new Figure 3—figure supplement 1C-D).</p><p>(iv) Finally, we also present new requested data demonstrating that <italic>P2ry1</italic> levels remain reduced across the 24-hr day, and that rhythmic expression is lost in synchronized <italic>Bmal1<sup>-/-</sup></italic> pseudoislets (new Figure 4—figure supplement 1B). This new data, in combination with our previous genomics evidence for enrichment of BMAL1 binding sites within the <italic>P2ry1</italic> enhancer region (Figure 4A, Figure 4—figure supplement 1A), support a direct role for BMAL1 in regulation of <italic>P2ry1</italic>.</p><p>p8. We have added the following text: “We also found decreased levels and loss in rhythmicity of P2ry1 in synchronized Bmal1<sup>-/-</sup> pseudoislets (Figure 4—figure supplement 1B). BMAL1 chromatin immunoprecipitation-sequencing in Β-TC-6 cells also revealed enrichment of BMAL1 chromatin binding within enhancer regions 266 – 41 kb upstream of the P2ry1 gene transcription start site (GSE69889) (Figure 4A, Figure 4—figure supplement 1A).”</p><disp-quote content-type="editor-comment"><p>3) Discuss novelty compared to Burns et al., 2015.</p></disp-quote><p>We thank the reviewers for the opportunity to expand upon the novelty of our screen in reference to previous publications, including that of Burns et al., 2015 (2). We designed our screen to identify small molecules and pharmacologic targets that can augment glucose-coupled insulin secretion in the context of impaired β cell function following abrogation of the molecular clock. In contrast, Burns et al., sought to identify compounds that activate or repress glucose-coupled insulin secretion in two strains of wild-type β cells in the absence of disease. Since molecular pathways that drive insulin secretion are perturbed during disease (3-5), we sought to identify compounds and pathways that effectively augment insulin secretion despite alterations in molecular pathways present in the diseased state. While this does not exclude compounds that effectively enhance insulin secretion in the “healthy” cell, we reasoned that our phenotype-driven approach would increase the sensitivity to identify targets with high predictive validity. Therefore, our concept was to leverage circadian mutant β cells as a rare (monogenic) form of diabetes, with the goal of uncovering insulinotropic mechanisms downstream of the molecular clock and at the same time finding targets that may have broad applicability as anti-hyperglycemic agents. We believe that our effort was fruitful insofar as our studies have shown insulinotropic effects of IVM in three independent models of β-cell failure, including in <italic>Bmal1</italic> KO, <italic>Cry</italic> double KO, and <italic>Akita</italic> diabetic mice (Figure 3B-D, Figure 3—figure supplement 1F-G).</p><p>To directly compare the results of our study with those found in Burns et al., we tabulated Z-scores of similarly annotated compounds side-by-side between our screen and those performed in INS1E and MIN6 cells in Burns et al., 2015 (<xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>). Of note, two lead compounds (ivermectin and tyrothricin) in Burns et al., had a positive Z-score in both INS1E and MIN6 cells, consistent with findings from our study (Figure 2B-D). In contrast, suloctidil was found to be insulinotropic in our screen but insulin-repressive in the Burns study. Further, while the compounds bufexamac, doramectin, moxidectin, and lobendazole were efficacious in promoting insulin secretion in wild-type MIN6 cells, these were found to be either ineffective (Z-score &lt; 1) or inhibitory for insulin secretion in BMAL1-ablated cells, which suggests these compounds may be ineffective in treating diabetes with a circadian component. Finally, potent inhibitors of insulin secretion in both screens included the calcium channel blockers isradipine and nitrendipine, consistent with a role for ca<sup>2+</sup> influx in β-cell physiology (6, 7). Together, these results highlight the importance of studying compounds in a context where the assay model (circadian disruption) reflects the relevant disease (type 2 diabetes).</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>Comparison of our circadian small molecule screen to Burns et al.</title><p>, 2015 screen. The hits from each screen were compared by analyzing Z-scores, which reflect the compounds’ insulin-secretory effects on <italic>Bmal1<sup>-/-</sup></italic> Β-TC-6 cells (our screen) versus the cell-types used by Burns et al., wild-type MIN6 (left) and INS1E cells (right), in the presence of glucose.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75132-sa2-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Type 2 diabetes (T2D) is a prevalent metabolic disease that is phenotypically characterized by the loss of ß cell secretory function and cell mass. Its pathophysiology is complex and includes a combination of genetic and environmental risk factors. Studies in humans suggest that circadian misalignment (e.g. under shift work schedules) and disrupted sleep are associated with an increased incidence of T2D, as well as signs of ß cell failure and insulin insensitivity. In addition, mouse studies have confirmed that deletions of key components of the molecular clock disrupt normal glucose homeostasis, ß cell function, and insulin secretion. Global Bmal1 KO and pancreatic Bmal1 KO have been shown to negatively impact glucose tolerance, glucose stimulated insulin secretion, and pancreatic islet size. However, despite a relatively clear connection between circadian disruption and risk for development of T2D, molecular mechanisms are yet to be described in detail and hold potential for contributing to the development of novel therapeutic and preventative strategies.</p><p>The authors aim to tackle these questions by identifying pharmacological compounds that improve the phenotype of circadian ß cell failure, as well as by further describing the mode of action of their final target compound.</p><p>1) Do the authors believe that the pharmacological compound hit they identify in their screen is specific for Bmal1 KO induced ß cell failure or is the disruption of circadian rhythmicity more important than knock-out of this specific gene? Since they have the insulin-nanoluciferase reporter and the compound library they could perform a smaller sub-screen with selected candidates in a model of circadian ß cell failure that is different from Bmal1 KO.</p></disp-quote><p>The Reviewer raises the important question about whether IVM-enhanced GSIS in the <italic>Bmal1<sup>-/-</sup></italic> β cells is specific to loss of the BMAL1 transcription factor itself, or whether IVM rescues GSIS in other models of clock network disruption. As described above in the response to Essential Revisions Point #1, we provide new data demonstrating that IVM also enhances GSIS in an independent model of circadian disruption (<italic>Cry1<sup>-/-</sup>; Cry2<sup>-/-</sup></italic>) (new Figure 3D in response to Essential Revisions Point #1), in addition to <italic>Bmal1<sup>-/-</sup></italic> cells. Inclusion of this new data suggests that the restoration of insulin secretion in the <italic>Bmal1<sup>-/-</sup></italic> cells by IVM is due to rescue of a defect caused by the circadian clock network itself as opposed a non-circadian effect of deletion of a specific transcription factor. We have added this new data to the manuscript as described above in the response to Essential Revisions Point #1.</p><disp-quote content-type="editor-comment"><p>2) My impression was that the authors are interested in finding pharmacological compounds that can rescue circadian ß cell failure. However, many of their results show that ivermectin also enhances insulin secretion in wild type cells/islets. So what is the conclusion of the authors? Did they just find &quot;another drug for treatment of ß cell failure&quot; or is it really specific for ß cell failure originating from circadian disruption (or perhaps Bmal1 KO)? If the former is the case, what would be the benefit of performing a compound screen in Bmal1 KO ß cells rather then in other established models of ß cell failure or wild type ß cells?</p></disp-quote><p>The Reviewer raises an interesting point regarding our finding that IVM enhances insulin secretion in the setting of both circadian disruption and in wild-type β cells. In our revised manuscript, we clarify that we specifically designed our screen to identify small molecules and pharmacologic targets that can augment glucose-coupled insulin secretion in the context of impaired β cell function following abrogation of the molecular clock. We chose this phenotype-driven approach to identify compounds and pathways that effectively augment insulin secretion despite alterations in molecular pathways present in the diseased state, with the goal of uncovering insulinotropic mechanisms downstream of the molecular clock and at the same time finding targets that may have broad applicability as anti-hyperglycemic agents.</p><p>We note that this does not exclude identification of compounds that effectively enhance insulin secretion in the “healthy” cell (as the Reviewer noted). The finding that IVM enhances glucose-stimulated insulin secretion in wild-type islets in addition to <italic>Bmal1</italic> KOs does not diminish the novel observation that IVM is able to augment insulin secretion during clock disruption. We identified pharmacologic activation of the P2Y1 receptor as a potential therapeutic avenue by using a genetic-sensitized screen, combined with genomics analyses in the <italic>Bmal1</italic> KO islets. Since the phenotype of the circadian mutant β cells used in this screen overlaps with features of β-cell failure found in T2D, we expect the hits from this screen to be more predictive of therapeutic effect in diabetes relative to those identified in healthy β cells. Supporting this hypothesis, we found IVM to be efficacious in enhancing glucose-responsive insulin secretion in multiple models of insulin secretion defects, including circadian-disrupted <italic>Cry</italic> double KOs and <italic>Akita</italic> islets. Future studies on the transcriptional networks shared between these models and how BMAL1::CLOCK/NPAS2 regulate physiological activity of purinergic receptors are warranted.</p><p>An additional perspective as to the utility of the genetically-sensitized circadian mutant screen is that many insulinotropic factors in WT cells, such as those directly inducing depolarization via closure of the potassium sulfonylurea channel, would not stimulate insulin secretion in the setting of circadian mutant cells (12)—in essence the approach we’ve taken of using mutant cells as a first level of screening provides a “filter” to enhance detection of “hit” compounds that might work in mutant cells and likewise reveal mechanistic insight into the circadian basis for β-cell function. We speculate that phenotype-driven screens similar to our present study can in the future expand using cell-based assays as a starting point to identify insulinotropic compounds and mechanisms involved in rare genetic (i.e. MODY mutations) and even more common environmental (i.e. lipoglucotoxicity models) conditions.</p><disp-quote content-type="editor-comment"><p>Specifically, I am referring to Figures Figure 3: Here the authors show that ivermectin treatment enhances glucose dependent insulin secretion, calcium influx, and membrane capacitance also in wild type islets. Why did they not test the effect of ivermectin on calcium influx and on insulin secretion in the perifusion system using their Bmal1 mutant islets?</p></disp-quote><p>We now provide new data demonstrating a decrease in glucose-stimulated insulin release during dynamic perifusion experiments in <italic>Bmal1<sup>-/-</sup></italic> islets that is restored in the presence of IVM, supporting a role for IVM-augmentation of glucose-stimulated insulin secretion in a model of clock disruption (see detailed response to Essential Revisions Point #1, new Figure 3C).</p><disp-quote content-type="editor-comment"><p>Generally the effect of ivermectin in wild type cells/islets appears somewhat inconsistent. For example, it does not enhance membrane capacitance in wild type mouse islets but it does enhance it in human islets. In Figure 3D glucose + ivermectin treatment completely rescues insulin release in Bmal1 mutant islets (release is similar to wild type levels) but in Figure 4D it does not. Can the authors discuss this?</p></disp-quote><p>Our insulin secretion and calcium influx experiments consistently show that IVM increases secretion and calcium flux in WT mouse cells and islets, as well as in islets from control mice in our <italic>Bmal1</italic> and <italic>Cry</italic> mutant experiments (Figures 2D, 3A-D 4B-D, Figure 3—figure supplement 1A-C). IVM treatment also enhances membrane capacitance in human islets (Figure 3F) though as the Reviewer noted, IVM did not result in a significant increase in membrane capacitance in control mouse islets (Figure 3E), which could be a result of either a small sample size (n=4 experiments with IVM in controls) or alternatively that capacitance under these conditions is already maximally stimulated in control islets, thereby preventing a further increase in capacitance following IVM stimulation.</p><p>We further note that our experiments also consistently show that IVM increases insulin release and calcium flux in circadian mutant cells and islets (Figures 3B-E, 4D), suggesting IVM can consistently rescue impaired secretory capacity in circadian mutants to physiological/wild-type levels, though the Reviewer notes there are differences in the degree of stimulation in the islets from <italic>Bmal1</italic> mutant mice in Figures 3B,D vs the pseudoislets from <italic>Bmal1</italic> mutant Β-TC-6 cells in Figure 4D, for example. Given our evidence that IVM augments P2Y1 signaling, it is possible that islet cell-to-cell paracrine nucleosides (13) may be required for full IVM effect. Therefore, the differences in degree of stimulation in islets versus pseudoislets may represent a difference in β-cell versus mixed-islet-cell response to IVM. Future studies will seek to understand IVM effects on islet cell crosstalk and other islet hormones.</p><disp-quote content-type="editor-comment"><p>3) In their study from 2015, Burns et al., (Cell Metabolism, reference 76.) developed a insulin-gaussia luciferase reporter that to my understanding is identical to the insulin-nanoluciferase reporter except for exchange of the luciferase enzyme. Burns et al., also used their reporter system to screen for modifiers of insulin secretion in a high-throughput format. Could the authors please elaborate why they chose to replace aussian by nanoluciferase and what is novel/beneficial about their approach?</p></disp-quote><p>We thank the Reviewer for the opportunity to clarify the novelty of our approach compared to a previously published small molecule screens for insulinotropic compounds (Burns et al., 2015) (2). We first wish to clarify that we used a Proinsulin-NanoLuc lentiviral vector (Proinsulin-NanoLuc in pLX304) that was a gift from David Altshuler, senior author of the Burns et al., paper (Addgene plasmid #62057; http://n2t.net/addgene:62057). The plasmid we received contains a Nano-luciferase insert as opposed to the Gaussia luciferase insert reported in Burns et al., 2015. For this reason, we independently validated our screen against an insulin immunoassay (Figure 1C). We note that Nanoluciferase is a slightly smaller construct (19 kDa) than the Gaussian luciferase (20 kDa), but both emit light in response to the compound substrate (i.e. Nano-Glo Substrate, Promega) in an ATP-independent manner.</p><p>Regarding novelty of our approach, as described above in the Essential Revisions Point #3, we designed our screen to identify small molecules and pharmacologic targets that can augment glucose-coupled insulin secretion in the context of impaired β cell function following abrogation of the molecular clock. Burns et al., on the other hand, sought to identify compounds that either activate or repress glucose-coupled insulin secretion in two strains of wild-type β cells in the absence of disease. Thus, we sought to identify compounds and pathways that effectively augment insulin secretion despite alterations in molecular pathways present in the diseased state. While this does not exclude compounds that effectively enhance insulin secretion in the “healthy” cell, we reasoned that our phenotype-driven approach would increase the sensitivity to identify targets with high predictive validity. Therefore, our concept was to leverage circadian mutant β cells as a rare (monogenic) form of diabetes, with the goal of uncovering insulinotropic mechanisms downstream of the molecular clock and at the same time finding targets that may have broad applicability as anti-hyperglycemic agents. We believe that our effort was fruitful insofar, as our studies showed insulinotropic effects of IVM in three independent models of β-cell failure, including <italic>Bmal1</italic> KO and <italic>Cry</italic> double KO mice as well as in the setting of the <italic>Akita</italic> diabetic mouse (Figure 3B-D, Figure 3—figure supplement 1F-G).</p><p>Finally, to compare the results of our study with those found in Burns et al., we tabulated Z-scores of similarly annotated compounds side-by-side between our screen and the screens performed using INS1E and MIN6 cells in Burns et al., 2015 (see <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>). Of note, two lead compounds (ivermectin and tyrothricin) in Burns et al., had a positive Z-score in both INS1E and MIN6 cells, consistent with findings from our study. In contrast, suloctidil was found to be insulinotropic in our screen but insulin-repressive in the Burns study. Further, while the compounds bufexamac, doramectin, moxidectin, and lobendazole were efficacious in promoting insulin secretion in wild-type MIN6 cells, these were found to be either ineffective (Z-Score &lt; 1) or inhibitory for insulin secretion in BMAL1-ablated cells, which suggests these compounds may be ineffective in treating diabetes with a circadian component. Finally, potent inhibitors of insulin secretion in both screens included the calcium channel blockers isradipine and nitrendipine, consistent with a role for ca<sup>2+</sup> influx in β-cell physiology (6, 7). Together, these results highlight the importance of studying compounds in a context where the assay model (circadian disruption) reflects the relevant the disease (type 2 diabetes).</p><disp-quote content-type="editor-comment"><p>4) Some important experimental controls are missing in some of the experiments (as follows).</p></disp-quote><p>We now include the below-mentioned controls in our revised manuscript:</p><disp-quote content-type="editor-comment"><p>Figure 3B – why are Bmal1 KO islets not included?</p><p>Figure 3C – again, why no Bmal1 KO islets?</p></disp-quote><p>We now show new data demonstrating a decrease in glucose-stimulated insulin release during dynamic perifusion experiments in <italic>Bmal1</italic> KO pseudoislets that is restored in the presence of IVM, supporting a role for IVM-augmentation of glucose-stimulated insulin secretion in a model of clock disruption (see detailed response to Essential Revisions Point #2 and new Figure 3C). We found that BMAL1-deficient β cells fail to appropriately respond to glucose in the context of the calcium influx assay performed in the original Figure 3B, which utilizes a nutrient deplete media; thus continued work to optimize and identify different key factors influencing wild-type versus circadian mutant performance in the context of calcium influx will be the subject of future studies.</p><disp-quote content-type="editor-comment"><p>Figure 4B – why is there no control with no glucose and just MRS?</p><p>Figure 4C – again, why is there no control with just MRS?</p></disp-quote><p>We now present new data demonstrating the P2Y1 inhibitor MRS has no effect on insulin secretion or calcium influx in the absence of glucose (see detailed response to Essential Revisions Point #2 and new Figures 4B-C)</p><disp-quote content-type="editor-comment"><p>Figure S2D – 0mM glucose + Isr is missing</p><p>Figure S2E – again control with just Isr is missing</p></disp-quote><p>We now include the requested 0 mM glucose + Isr control and reveal decreases in insulin secretion and calcium influx following calcium channel inhibition with Isr in the absence of glucose (see detailed response to Essential Revisions Point #2 and new Figure 3—figure supplement 1C-D)</p><disp-quote content-type="editor-comment"><p>Figure S3B – P2ry1 transcript is rhythmic in wild type ß cells but is it's rhythmicity really lost in Bmal1 KO ß cells? (if the authors claim that P2ry1 is regulated by BMAL1 they should check this)</p></disp-quote><p>We now present new data demonstrating that <italic>P2ry1</italic> levels remain reduced and arhythmic across the 24-hr day in synchronized <italic>Bmal1<sup>-/-</sup></italic> pseudoislets (see detailed response to Essential Revisions Point #2 and new Figure 4—figure supplement 1B), supporting a direct role for BMAL1 in regulation of <italic>P2ry1</italic>.</p><disp-quote content-type="editor-comment"><p>Also it is unclear why for some experiments the authors used 2mM &quot;basal glucose&quot; as control condition and sometimes they used 0mM glucose. Could they please explain?</p></disp-quote><p>We have clarified in the methods that for the GSIS assays performed in primary islets, we used 2 mM glucose as the basal glucose concentration, which is standard in the field (14). We further clarified that 0 mM glucose was used as the basal glucose concentration for all GSIS assays performed in either β cell lines or pseudoislets in order to minimize the typically higher levels of unstimulated glucose-stimulated insulin secretion that occurs in β cell lines compared to islets (5).</p><disp-quote content-type="editor-comment"><p>5) Could the authors elaborate on their strategy to identify potential ivermectin targets? It appears that ivermectin also augments insulin secretion in wild type cells, so is it really logical to check for transcripts that are already highly expressed in wild type? Wouldn't it be more intuitive to look for the top differentially expressed genes in wild type vs. Bmal1 KO ß cells? Also I would like to point out that the display of the differential gene expression data (Figure S3A) is difficult to understand for the reader. Rather than plotting the p-value the authors could show the log-fold change of expression (or similar) so that the reader can comprehend Bmal1 KO induced changes.</p></disp-quote><p>Strategy to identify potential IVM targets<italic>:</italic> To identify potential IVM targets, we first performed a literature review to identify previously-published IVM targets to use as starting points, which included ion channels, G-protein coupled receptors, ionotropic receptors (such as purinergic, GABAergic, and glycine receptors), as well as farnesoid X nuclear receptors (15, 16). Our observations that IVM rapidly increases calcium flux and insulin release in a glucose-dependent manner argues against a role for a transcriptional regulator (FXR) or a direct ionophore effect (GABA) and is more consistent with a role for β-cell G-protein coupled receptor activation, which requires glucose for appropriate signaling (17, 18). Recently, P2Y1 was implicated in nutrient- and ATP/ADP-dependent regulation of insulin release through an adipocyte-islet axis, further suggesting P2Y1 may play a role in physiologic regulation of islet hormone release (13). Additional studies will be required to determine whether IVM affects paracrine ATP/ADP release to affect P2Y1 or whether IVM directly binds purinergic receptors in the β cell.</p><p>Analysis of differentially-expressed genes in BKOs to provide insight to potential candidates: Next, in agreement with the Reviewer’s suggestion, we considered top differentially-expressed genes in the WT vs <italic>Bmal1<sup>-/-</sup></italic> β cells from our RNA-seq analyses. To clarify these findings in the text, we re-organized our Results section and now begin with data showing that <italic>P2ry1</italic> is one of the most differentially-expressed genes in the <italic>Bmal1<sup>-/-</sup></italic> β cells, with a 3.1-fold reduction (Adj. P=10<sup>-55</sup>) in expression (Figure 4A). We have also updated Figure S3A as requested to include the log-fold change of <italic>P2ry1</italic> in addition to the p-value (Figure 4—figure supplement 1A, <xref ref-type="fig" rid="sa2fig2">Author response image 2</xref>). Further support for BMAL1 control of <italic>P2ry1</italic> is enriched BMAL1 chromatin binding within enhancer regions 266-41 kb upstream of the <italic>P2ry1</italic> gene transcription start site by ChIP-sequencing (Figure 4A, Figure 4—figure supplement 1A), rhythmic expression of <italic>P2ry1</italic> in WT Β-TC-6 pseudoislets (Figure 4—figure supplement 1B), and new data showing loss of rhythmic <italic>P2ry1</italic> expression in <italic>Bmal1<sup>-/-</sup></italic> pseudoislets (new Figure 4—figure supplement 1B).</p><fig id="sa2fig2" position="float"><label>Author response image 2.</label><caption><title>Robust differential expression of <italic>P2ry1</italic> following BMAL1 ablation.</title><p>The <italic>P2ry1</italic> transcript is one of the most abundant receptors in the broad class of putative IVM targets and was identified following BMAL1 ablation as one of the most consistently and highly repressed transcripts (Adj. P &lt; 10<sup>-55</sup>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75132-sa2-fig2-v1.tif"/></fig><p>Thus, since it is known that IVM augments purinergic signaling (19, 20), that the purinergic receptor P2Y1 is significantly reduced in <italic>Bmal1<sup>-/-</sup></italic> β cells, and that BMAL1 specifically controls <italic>P2ry1</italic> amongst the purinergic receptor family in the β cell (Figure 4A, Figure 4—figure supplement 1A-B), we sought to test the functional role of the P2Y1 receptor in the insulinotropic action of IVM. While we cannot rule out potential action of IVM on other targets, evidence from our pharmacologic and genetic <italic>P2ry1</italic> ablation models suggest P2Y1 is a critical component of the IVM insulinotropic effect.</p><p>References</p><p>1. Segerstolpe A, Palasantza A, Eliasson P, Andersson EM, Andreasson AC, Sun X, Picelli S, Sabirsh A, Clausen M, Bjursell MK, Smith DM, Kasper M, Ammala C, Sandberg R. Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes. Cell Metab. 2016;24(4):593-607. Epub 2016/09/27. doi: 10.1016/j.cmet.2016.08.020. PubMed PMID: 27667667; PMCID: PMC5069352.</p><p>2. Burns SM, Vetere A, Walpita D, Dancik V, Khodier C, Perez J, Clemons PA, Wagner BK, Altshuler D. High-throughput luminescent reporter of insulin secretion for discovering regulators of pancreatic Β-cell function. Cell Metab. 2015;21(1):126-37. Epub 2015/01/08. doi: 10.1016/j.cmet.2014.12.010. PubMed PMID: 25565210.</p><p>3. Perelis M, Marcheva B, Ramsey KM, Schipma MJ, Hutchison AL, Taguchi A, Peek CB, Hong H, Huang W, Omura C, Allred AL, Bradfield CA, Dinner AR, Barish GD, Bass J. Pancreatic β cell enhancers regulate rhythmic transcription of genes controlling insulin secretion. Science. 2015;350(6261):aac4250. doi: 10.1126/science.aac4250. PubMed PMID: 26542580; PMCID: 4669216.</p><p>4. Avrahami D, Wang YJ, Schug J, Feleke E, Gao L, Liu C, Consortium H, Naji A, Glaser B, Kaestner KH. Single-cell transcriptomics of human islet ontogeny defines the molecular basis of β-cell dedifferentiation in T2D. Mol Metab. 2020;42:101057. Epub 2020/08/03. doi: 10.1016/j.molmet.2020.101057. PubMed PMID: 32739450; PMCID: PMC7471622.</p><p>5. Marcheva B, Perelis M, Weidemann BJ, Taguchi A, Lin H, Omura C, Kobayashi Y, Newman MV, Wyatt EJ, McNally EM, Fox JEM, Hong H, Shankar A, Wheeler EC, Ramsey KM, MacDonald PE, Yeo GW, Bass J. A role for alternative splicing in circadian control of exocytosis and glucose homeostasis. Genes Dev. 2020;34(15-16):1089-105. Epub 2020/07/04. doi: 10.1101/gad.338178.120. PubMed PMID: 32616519; PMCID: PMC7397853.</p><p>6. Schulla V, Renstrom E, Feil R, Feil S, Franklin I, Gjinovci A, Jing XJ, Laux D, Lundquist I, Magnuson MA, Obermuller S, Olofsson CS, Salehi A, Wendt A, Klugbauer N, Wollheim CB, Rorsman P, Hofmann F. Impaired insulin secretion and glucose tolerance in β cell-selective Ca(v)1.2 ca<sup>2+</sup> channel null mice. EMBO J. 2003;22(15):3844-54. Epub 2003/07/26. doi: 10.1093/emboj/cdg389. PubMed PMID: 12881419; PMCID: PMC169062.</p><p>7. Vasseur M, Debuyser A, Joffre M. Sensitivity of pancreatic β cell to calcium channel blockers. An electrophysiologic study of verapamil and nifedipine. Fundam Clin Pharmacol. 1987;1(2):95-113. Epub 1987/01/01. doi: 10.1111/j.1472-8206.1987.tb00549.x. PubMed PMID: 3315915.</p><p>8. Bult CJ, Blake JA, Smith CL, Kadin JA, Richardson JE, Mouse Genome Database G. Mouse Genome Database (MGD) 2019. Nucleic Acids Res. 2019;47(D1):D801-D6. Epub 2018/11/09. doi: 10.1093/nar/gky1056. PubMed PMID: 30407599; PMCID: PMC6323923.</p><p>9. Gorgani NN, Smith BA, Kono DH, Theofilopoulos AN. Histidine-rich glycoprotein binds to DNA and Fc γ RI and potentiates the ingestion of apoptotic cells by macrophages. J Immunol. 2002;169(9):4745-51. Epub 2002/10/23. doi: 10.4049/jimmunol.169.9.4745. PubMed PMID: 12391183.</p><p>10. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46-52. Epub 1986/01/01. doi: 10.1007/BF02427280. PubMed PMID: 3514343.</p><p>11. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-705. Epub 2006/11/14. doi: 10.1016/S0140-6736(06)69705-5. PubMed PMID: 17098089.</p><p>12. Marcheva B, Ramsey KM, Buhr ED, Kobayashi Y, Su H, Ko CH, Ivanova G, Omura C, Mo S, Vitaterna MH, Lopez JP, Philipson LH, Bradfield CA, Crosby SD, Jebailey L, Wang X, Takahashi JS, Bass J. Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. Nature. 2010;466(7306):571-2. Epub 2010/06/22. doi: nature09253 [pii]10.1038/nature09253. PubMed PMID: 20562852.</p><p>13. Prentice KJ, Saksi J, Robertson LT, Lee GY, Inouye KE, Eguchi K, Lee A, Cakici O, Otterbeck E, Cedillo P, Achenbach P, Ziegler AG, Calay ES, Engin F, Hotamisligil GS. A hormone complex of FABP4 and nucleoside kinases regulates islet function. Nature. 2021;600(7890):720-6. Epub 2021/12/10. doi: 10.1038/s41586-021-04137-3. PubMed PMID: 34880500.</p><p>14. Carter JD, Dula SB, Corbin KL, Wu R, Nunemaker CS. A practical guide to rodent islet isolation and assessment. Biol Proced Online. 2009;11:3-31. Epub 2009/12/04. doi: 10.1007/s12575-009-9021-0. PubMed PMID: 19957062; PMCID: PMC3056052.</p><p>15. Chen IS, Kubo Y. Ivermectin and its target molecules: shared and unique modulation mechanisms of ion channels and receptors by ivermectin. J Physiol. 2018;596(10):1833-45. Epub 2017/10/25. doi: 10.1113/JP275236. PubMed PMID: 29063617; PMCID: PMC5978302.</p><p>16. Dawson GR, Wafford KA, Smith A, Marshall GR, Bayley PJ, Schaeffer JM, Meinke PT, McKernan RM. Anticonvulsant and adverse effects of avermectin analogs in mice are mediated through the γ-aminobutyric acid(A) receptor. J Pharmacol Exp Ther. 2000;295(3):1051-60. Epub 2000/11/18. PubMed PMID: 11082440.</p><p>17. Gilon P, Henquin JC. Mechanisms and physiological significance of the cholinergic control of pancreatic β-cell function. Endocr Rev. 2001;22(5):565-604. Epub 2001/10/06. doi: 10.1210/edrv.22.5.0440. PubMed PMID: 11588141.</p><p>18. Leon C, Freund M, Latchoumanin O, Farret A, Petit P, Cazenave JP, Gachet C. The P2Y(1) receptor is involved in the maintenance of glucose homeostasis and in insulin secretion in mice. Purinergic Signal. 2005;1(2):145-51. Epub 2008/04/12. doi: 10.1007/s11302-005-6209-x. PubMed PMID: 18404499; PMCID: PMC2096536.</p><p>19. Bowler JW, Bailey RJ, North RA, Surprenant A. P2X4, P2Y1 and P2Y2 receptors on rat alveolar macrophages. Br J Pharmacol. 2003;140(3):567-75. Epub 2003/09/13. doi: 10.1038/sj.bjp.0705459. PubMed PMID: 12970084; PMCID: PMC1574050.</p><p>20. Hansen MR, Krabbe S, Novak I. Purinergic receptors and calcium signalling in human pancreatic duct cell lines. Cell Physiol Biochem. 2008;22(1-4):157-68. Epub 2008/09/05. doi: 10.1159/000149793. PubMed PMID: 18769042.</p><p>21. von der Kammer H, Demiralay C, Andresen B, Albrecht C, Mayhaus M, Nitsch RM. Regulation of gene expression by muscarinic acetylcholine receptors. Biochem Soc Symp. 2001(67):131-40. Epub 2001/07/13. doi: 10.1042/bss0670131. PubMed PMID: 11447829.</p><p>22. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. RNA-guided human genome engineering via Cas9. Science. 2013;339(6121):823-6. Epub 2013/01/05. doi: 10.1126/science.1232033. PubMed PMID: 23287722; PMCID: PMC3712628.</p><p>23. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281-308. Epub 2013/10/26. doi: 10.1038/nprot.2013.143. PubMed PMID: 24157548; PMCID: PMC3969860.</p><p>24. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157(6):1262-78. Epub 2014/06/07. doi: 10.1016/j.cell.2014.05.010. PubMed PMID: 24906146; PMCID: PMC4343198.</p></body></sub-article></article>